var title_f36_21_37200="Congenital hypothyroid screen";
var content_f36_21_37200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Evaluation of an infant with an abnormal screening test for hypothyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 535px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37200=[""].join("\n");
var outline_f36_21_37200=null;
var title_f36_21_37201="Frozen shoulder";
var content_f36_21_37201=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Frozen shoulder (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/21/37201/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37201/contributors\" id=\"au5319\">",
"       Bruce C Anderson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/21/37201/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37201/contributors\" id=\"se7143\">",
"       Karl B Fields, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/21/37201/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37201/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/21/37201?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FROZEN SHOULDER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Frozen shoulder is the term used to describe a stiff shoulder joint that has temporarily lost the ability to move freely; most people with frozen shoulder have difficulty reaching overhead and reaching to the low back. The stiffening is the body's natural response to inflammation that develops in or near the shoulder. Stiffening is a protective reflex that protects the shoulder from further injury.",
"    </p>",
"    <p>",
"     In 95 percent of cases, frozen shoulder is totally reversible, although full recovery may take several months. Stretching exercises are the treatments of choice for frozen shoulder.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FROZEN SHOULDER TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Limit activity",
"     </span>",
"     &nbsp;&mdash;&nbsp;During recovery, you should limit overhead positioning, reaching, and lifting. These restrictions can be eased as pain decreases and flexibility increases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;If needed, a non-prescription pain medication such as acetaminophen (Tylenol&reg;), ibuprofen (eg, Advil&reg;, Motrin&reg;), or naproxen (eg, Aleve&reg;) can be taken. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .) No more than 4000 mg of acetaminophen is recommended per day. Anyone with liver disease or who drinks alcohol regularly should speak with his or her healthcare provider before taking acetaminophen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Ice the joint",
"     </span>",
"     &nbsp;&mdash;&nbsp;Apply an ice pack or bag of frozen vegetables to the shoulder for 15 minutes every four to six hours to reduce pain and inflammation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      FROZEN SHOULDER STRETCHING EXERCISES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Heat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heat helps prepare the tissues for stretching and should be performed prior to exercise sessions. The preferable method of heating is in a warm shower or bath for 10 to 15 minutes. Local heat (for example with a moist heating pad or a towel warmed in a microwave) is an alternative, but generally is not as effective.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Weighted pendulum stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Range-of-motion exercises are recommended early in the recovery period. These exercises are intended to help maintain joint mobility and flexibility of the muscles and tendons in the shoulder. Pain should not exceed mild levels with any",
"     <span class=\"nowrap\">",
"      range-of-motion/flexibility",
"     </span>",
"     exercise. Anyone who feels sharp or tearing pain while stretching should stop exercising immediately and consult with a healthcare provider.",
"    </p>",
"    <p>",
"     The weighted pendulum stretching exercise performs two functions:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gently stretches the space in which the tendons pass to relieve pressure on the tendons",
"      </li>",
"      <li>",
"       Prevents the development of a frozen (stiff) shoulder",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This exercise can be started almost immediately after a shoulder injury, or after receiving a steroid injection into the shoulder joint. This exercise should be performed after heating for five minutes once or twice per day. The exercise is performed as follows (",
"     <a class=\"graphic graphic_figure graphicRef50148 \" href=\"mobipreview.htm?12/37/12895\">",
"      figure 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Relax your shoulder muscles.",
"      </li>",
"      <li>",
"       While standing or sitting, keep your arm vertical and close to your body (bending over too far may pinch the rotator cuff tendons).",
"      </li>",
"      <li>",
"       Allow your arm to swing forward to back, then side to side, then in small circles in each direction (no greater than 1 foot in any direction). Only minimal pain should be felt.",
"      </li>",
"      <li>",
"       Stretch the arm only (without added weight) for three to seven days. Progress this exercise by adding 1 to 2 pounds (0.5 to 1 kg) each week and gradually increasing the diameter of the movements (not to exceed 18 to 24 inches or 45 to 60 cm).",
"      </li>",
"      <li>",
"       After a few weeks this exercise should be supplemented or replaced by other exercises to target specific areas of",
"       <span class=\"nowrap\">",
"        tightness/restriction.",
"       </span>",
"       The pendulum stretch may be recommended as a warm up for more localized flexibility exercises",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       strengthening exercises.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When performed correctly the pendulum exercise should not result in more than mild discomfort. If more pain is felt, consult a healthcare provider for instructions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Passive stretching exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Passive stretches (ie, stretches done without actively contracting any shoulder muscles) should be performed after the pendulum stretch exercise. These exercises should further loosen the tightened shoulder capsule and muscles and restore normal range of motion. These exercises should be performed in sets of 10 to 20 once or twice a day for several months. The goal of these exercises is to stretch the shoulder to the point of tension but not pain. Severe discomfort is unusual and suggests overstretching.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Armpit stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Use your good arm to lift the affected arm onto a shelf, dresser, or any object that is chest high (",
"     <a class=\"graphic graphic_picture graphicRef51493 \" href=\"mobipreview.htm?9/4/9295\">",
"      picture 1",
"     </a>",
"     ). Gently bend at the knees, opening up the armpit. Try to push the affected arm up a little farther with each stretch.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Finger walk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Face a wall about three-quarters of an arm's length away (",
"     <a class=\"graphic graphic_picture graphicRef78109 \" href=\"mobipreview.htm?13/8/13455\">",
"      picture 2",
"     </a>",
"     ). Using only your fingers (not your shoulder muscles) raise your arm up to shoulder level.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Towel stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;Take a 3-foot-long towel, grasp it with both hands, and hold it at a 45 degree angle (",
"     <a class=\"graphic graphic_picture graphicRef77955 \" href=\"mobipreview.htm?20/47/21247\">",
"      picture 3",
"     </a>",
"     ). Use the upper, good arm to pull the arm toward the lower back. This can be repeated with the towel in the horizontal position.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      FROZEN SHOULDER STRENGTHENING EXERCISES",
"     </span>",
"    </p>",
"    <p>",
"     Muscle toning exercises may play a role in recovery from frozen shoulder, particularly if tendonitis occurred before developing a frozen shoulder. Your healthcare provider will advise you if these exercises are necessary. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=see_link\">",
"      \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The joint should be warmed with cardiovascular exercise or a warm pack and stretched with range-of-motion exercises before beginning strengthening exercises. Following a two to three minute rest, 10 to 15 sets of each strengthening exercise should be done once per day, holding each for five seconds. Flexible rubber tubing, a bungee cord, or a large rubber band is recommended for each exercise (",
"     <a class=\"graphic graphic_figure graphicRef70846 \" href=\"mobipreview.htm?26/2/26656\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Outward rotation exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hold your elbows at 90 degrees, close to your sides; holding a towel between your torso and the inside of your elbow will cue you to keep your elbow by your side. Hold one end of a rubber band in each hand and rotate the affected lower arm outward two or three inches, holding for five seconds (",
"     <a class=\"graphic graphic_picture graphicRef53514 \" href=\"mobipreview.htm?36/14/37089\">",
"      picture 4",
"     </a>",
"     ). Repeat 10 to 15 times.",
"    </p>",
"    <p>",
"     Perform the exercise through all available pain-free ranges of motion. Keep the shoulder blades squeezed down and back while performing this exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Inward rotation exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hold your elbow at 90 degrees, close to your side. Hook the rubber band onto a door handle and grasp with only one hand. Rotate your forearm towards the body two or three inches and hold for five seconds (",
"     <a class=\"graphic graphic_picture graphicRef67577 \" href=\"mobipreview.htm?3/14/3298\">",
"      picture 5",
"     </a>",
"     ). The forearm swings like a door. Repeat 10 to 15 times.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Abduction exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bend your elbow to 90 degrees. Place the rubber band near the elbows and lift your arms up four or five inches away from the body, holding for five seconds (",
"     <a class=\"graphic graphic_picture graphicRef55598 \" href=\"mobipreview.htm?18/9/18577\">",
"      picture 6",
"     </a>",
"     ). Repeat 10 to 15 times.",
"    </p>",
"    <p>",
"     Mild soreness should be expected with these exercises. Sharp or severe pain may indicate a flare of the underlying problem; stop these exercises for a few days if this occurs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      IF PAIN AND STIFFNESS CONTINUE",
"     </span>",
"    </p>",
"    <p>",
"     If pain and stiffness are still present after completing a course of physical therapy, a repeat examination may be recommended to determine if another problem, such as rotator cuff tendinitis, is present.",
"    </p>",
"    <p>",
"     If there is no other cause for symptoms, one of the following treatments may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Steroid injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Injecting a steroid into the shoulder joint may help to speed recovery over the short term, especially if a course of physical therapy is done after the injection.",
"    </p>",
"    <p>",
"     Following the steroid injection, it is important to limit activity, treat pain as needed, and begin stretching and strengthening exercises. (See",
"     <a class=\"local\" href=\"#H2\">",
"      'Frozen shoulder treatment'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6689219\">",
"     <span class=\"h2\">",
"      Joint dilation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Injecting fluid into the shoulder joint may increase joint space and improve motion. This technique may be performed if motion does not improve with physical therapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      RETURN TO ACTIVITIES AFTER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     If a steroid injection is given, it is important to protect the shoulder for 30 days by limiting reaching, overhead positioning, lifting, pushing, and pulling. Other regular activities, work, and sports should be avoided until the shoulder can move in all directions and muscle strength has improved by at least 75 percent.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287435076\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254581\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/26/22946?source=see_link\">",
"      Patient information: Frozen shoulder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=see_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/47/7923?source=see_link\">",
"      Patient information: Separated shoulder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/35/26162?source=see_link\">",
"      Patient information: Shoulder impingement (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H254596\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=see_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36425?source=see_link\">",
"      Radiologic evaluation of the painful shoulder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32280?source=see_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"      file://orthoinfo.aaos.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"      www.niams.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Physical Therapy Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.apta.org/\">",
"      www.apta.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Arthritis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.arthritis.org/\">",
"      www.arthritis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/21/37201/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 1, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/21/37201?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37201/abstract/1\">",
"      Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. J Bone Joint Surg Br 2007; 89:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37201/abstract/2\">",
"      Sheridan MA, Hannafin JA. Upper extremity: emphasis on frozen shoulder. Orthop Clin North Am 2006; 37:531.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_21_37201=[""].join("\n");
var outline_f36_21_37201=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FROZEN SHOULDER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FROZEN SHOULDER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           FROZEN SHOULDER STRETCHING EXERCISES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           FROZEN SHOULDER STRENGTHENING EXERCISES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           IF PAIN AND STIFFNESS CONTINUE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           RETURN TO ACTIVITIES AFTER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/37/12895\" title=\"figure 1\">",
"           Pendulum stretch exercise PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/2/26656\" title=\"figure 2\">",
"           Shoulder strength PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/4/9295\" title=\"picture 1\">",
"           Armpit stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/8/13455\" title=\"picture 2\">",
"           Walk up wall stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/47/21247\" title=\"picture 3\">",
"           Towel stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/14/37089\" title=\"picture 4\">",
"           Outward rotation PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/14/3298\" title=\"picture 5\">",
"           Inward rotation exercise PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/9/18577\" title=\"picture 6\">",
"           Lifting exercise PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37202="Rheumatoid leg ulcer";
var content_f36_21_37202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatoid arthritis: skin ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classic ulcer with granulomatous base and undermined gunmetal-colored border in patient with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37202=[""].join("\n");
var outline_f36_21_37202=null;
var title_f36_21_37203="Laronidase: Patient drug information";
var content_f36_21_37203=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Laronidase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/43/11957?source=see_link\">",
"     see \"Laronidase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/55/884?source=see_link\">",
"     see \"Laronidase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldurazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldurazyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691965",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mucopolysaccharidosis I.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to laronidase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lung infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen and diphenhydramine may be given before this drug to lower fever and chills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11178 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37203=[""].join("\n");
var outline_f36_21_37203=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854886\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017878\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017880\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017879\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017884\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017885\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017887\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017882\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017883\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017889\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/43/11957?source=related_link\">",
"      Laronidase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/55/884?source=related_link\">",
"      Laronidase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37204="Pravastatin: Patient drug information";
var content_f36_21_37204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pravastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     see \"Pravastatin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/2/17447?source=see_link\">",
"     see \"Pravastatin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pravachol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pravastatin&reg;;",
"     </li>",
"     <li>",
"      CO Pravastatin;",
"     </li>",
"     <li>",
"      Dom-Pravastatin;",
"     </li>",
"     <li>",
"      JAMP-Pravastatin;",
"     </li>",
"     <li>",
"      Mint-Pravastatin;",
"     </li>",
"     <li>",
"      Mylan-Pravastatin;",
"     </li>",
"     <li>",
"      Novo-Pravastatin;",
"     </li>",
"     <li>",
"      Nu-Pravastatin;",
"     </li>",
"     <li>",
"      PHL-Pravastatin;",
"     </li>",
"     <li>",
"      PMS-Pravastatin;",
"     </li>",
"     <li>",
"      Pravachol&reg;;",
"     </li>",
"     <li>",
"      RAN&trade;-Pravastatin;",
"     </li>",
"     <li>",
"      ratio-Pravastatin;",
"     </li>",
"     <li>",
"      Riva-Pravastatin;",
"     </li>",
"     <li>",
"      Sandoz-Pravastatin;",
"     </li>",
"     <li>",
"      Teva-Pravastatin;",
"     </li>",
"     <li>",
"      ZYM-Pravastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pravastatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11837 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37204=[""].join("\n");
var outline_f36_21_37204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013592\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013591\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013596\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013597\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013599\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013594\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013595\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013600\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013601\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=related_link\">",
"      Pravastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/2/17447?source=related_link\">",
"      Pravastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37205="Follitropin alfa (recombinant human follicle stimulating hormone): Drug information";
var content_f36_21_37205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Follitropin alfa (recombinant human follicle stimulating hormone): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/14/29924?source=see_link\">",
"    see \"Follitropin alfa (recombinant human follicle stimulating hormone): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3882602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gonal-f&reg;;",
"     </li>",
"     <li>",
"      Gonal-f&reg; RFF;",
"     </li>",
"     <li>",
"      Gonal-f&reg; RFF Pen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3888769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gonal-f&reg;;",
"     </li>",
"     <li>",
"      Gonal-f&reg; Pen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3882605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin;",
"     </li>",
"     <li>",
"      Ovulation Stimulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3882635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be individualized. Use the lowest dose consistent with the expectation of good results. Over the course of treatment, doses may vary depending on individual patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ovulation induction:",
"     </b>",
"     <i>",
"      Gonal-f&reg;, Gonal-f&reg; RFF:",
"     </i>",
"     Females: SubQ: Initial: 75 units/day; incremental  dose adjustments of up to 37.5 units may be considered after 14 days; further dose increases of the same magnitude can be made, if necessary, every 7 days (maximum dose: 300 units/day). If response to follitropin is appropriate, hCG is given 1 day following the last dose. Withhold hCG if serum estradiol is &gt;2000 pg/mL, if the ovaries are abnormally enlarged, or if abdominal pain occurs.  In general, therapy should not exceed 35 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ART:",
"     </b>",
"     <i>",
"      Gonal-f&reg;, Gonal-f&reg; RFF:",
"     </i>",
"     Females: SubQ: Initiate therapy with follitropin alfa in the early follicular phase (cycle day 2 or day 3) at a dose of 150 units/day, until sufficient follicular development is attained. In most cases, therapy should not exceed 10 days. In patients &ge;35 years whose endogenous gonadotropin levels are suppressed, initiate follitropin alfa at a dose of 225 units/day. Continue treatment until adequate follicular development is indicated as determined by ultrasound in combination with measurement of serum estradiol levels. Consider adjustments to dose after 5 days based on the patient's response; adjust subsequent dosage every 3-5 days by &le;75-150 units additionally at each adjustment. Doses &gt;450 units/day are not recommended. Once adequate follicular development is evident, administer hCG to induce final follicular maturation in preparation for oocyte retrieval. Withhold hCG if the ovaries are abnormally enlarged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Spermatogenesis induction:",
"     </b>",
"     <i>",
"      Gonal-f&reg;:",
"     </i>",
"     Males: SubQ: Therapy should begin with hCG pretreatment until serum testosterone is in normal range, then 150 units 3 times/week with hCG 3 times/week; continue with lowest dose needed to induce spermatogenesis (maximum dose: 300 units 3 times/week); may be given for up to 18 months",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3882636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Clinical studies did not include patients &gt;65 years.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13812856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13812857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gonal-f&reg;: 450 units, 1050 units [contains benzyl alcohol (in diluent), sucrose 30 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gonal-f&reg; RFF: 75 units [contains sucrose 30 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [rDNA origin]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gonal-f&reg; RFF Pen: 300 units/0.5 mL (0.5 mL); 450 units/0.75 mL (0.75 mL); 900 units/1.5 mL (1.5 mL) [contains sucrose 60 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3882604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3882637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gonal-f&reg;, Gonal-f&reg; RFF: Administer SubQ. Contents of multidose vials should be administered using the calibrated syringes provided by the manufacturer. Do not shake solution; allow any bubbles to settle prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gonal-f&reg;: Induction of ovulation in anovulatory infertile patients in whom the cause of infertility is functional and not caused by primary ovarian failure; development of multiple follicles with Assisted Reproductive Technology (ART); induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gonal-f&reg; RFF: Induction of ovulation in oligo-anovulatory infertile patients in whom the cause of infertility is functional and not caused by primary ovarian failure; development of multiple follicles with ART",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3882615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Percentage may vary by indication, product formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (males)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (males), ovarian cyst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, abdominal pain, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypotension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, emotional lability, fatigue, fever, malaise, migraine, nervousness, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (females), pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (females), cervix lesion, dysmenorrhea, gynecomastia, hot flashes, intermenstrual bleeding, menstrual disorder, ovarian disorder, ovarian hyperstimulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, flatulence, stomatitis (ulcerative), toothache, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis, leukorrhea, micturition frequency, pelvic pain, urinary tract infection, uterine hemorrhage, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site bruising, edema, inflammation, pain, reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, cough, dyspnea,  pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection, moniliasis, thirst increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing, case reports, or events reported with gonadotropins: Adnexal torsion, anaphylactoid reactions, Epstein-Barr virus, hemoperitoneum, hemoptysis, hypersensitivity reactions, ovarian enlargement, ovarian neoplasms, pulmonary complications, varicocele, vascular complications",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3882610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to follitropins or any component of the formulation; high levels of FSH indicating primary gonadal failure (ovarian or testicular); uncontrolled thyroid or adrenal dysfunction; tumor of the ovary, breast, uterus, hypothalamus, testis, or pituitary gland; abnormal vaginal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3882611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain, occurs in ~20% of those treated with urofollitropin and hCG, and generally regresses without treatment within 2-3 weeks. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome (OHSS): Reported in about 7% of patients; it is characterized by severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria, and may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events. If hyperstimulation occurs, stop treatment and hospitalize patient. This syndrome develops rapidly within 24 hours to several days, and generally occurs after treatment has ended and reaches its maximum on days 7-10  following treatment. Hemoconcentration associated with fluid loss into the abdominal cavity has occurred and should be assessed by fluid intake and output, weight, hematocrit, serum and urinary electrolytes, urine specific gravity, BUN and creatinine, and abdominal girth. Determinations should be performed daily or more often if the need arises. Treatment is primarily symptomatic and consists of bedrest, fluid and electrolyte replacement, and analgesics. The ascitic, pleural, and pericardial fluids should not be removed unless needed to relieve symptoms of cardiopulmonary distress.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Thromboembolic events: In association with and separate from ovarian hyperstimulation syndrome (OHSS), thromboembolic events have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple births: May result from the use of these medications; advise patient of the potential risk of multiple births before starting the treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3882606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3882607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after ART than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics). Follitropin Alfa is used for the induction of ovulation; use is contraindicated in women who are already pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3882609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if follitropin alfa is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gonal-f RFF Pen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 units/0.5 mL (0.5 mL): $554.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 unit/0.75 mL (0.75 mL): $831.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 unit/1.5 mL (1.5 mL): $1663.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Gonal-f Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 unit (1): $831.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1050 unit (1): $1940.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Gonal-f RFF Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 unit (1): $138.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3882639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor sufficient follicular maturation. This may be directly estimated by sonographic visualization of the ovaries and endometrial lining or measuring serum estradiol levels. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing hCG administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The clinical evaluation of estrogenic activity (changes in vaginal cytology and changes in appearance and volume of cervical mucus) provides an indirect estimate of the estrogenic effect upon the target organs and, therefore, it should only be used adjunctively with more direct estimates of follicular development (ultrasonography and serum estradiol determinations).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The clinical confirmation of ovulation is obtained by direct and indirect indices of progesterone production. The indices most generally used are: rise in basal body temperature, increase in serum progesterone, and menstruation following the shift in basal body temperature.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Monitor for signs and symptoms of OHSS for at least 2 weeks following hCG administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Spermatogenesis: Monitor serum testosterone levels, sperm count",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gonal-F (AR, AT, AU, BE, BG, BR, CH, CL, CN, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SE, SG, SK, SV, TR, TW);",
"     </li>",
"     <li>",
"      Gonalef (VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3882624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follitropin alfa is a human FSH preparation of recombinant DNA origin. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure, and stimulate spermatogenesis in men with hypogonadotrophic hypogonadism. FSH is required for normal follicular growth, maturation, gonadal steroid production, and spermatogenesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3882626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Peak effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Spermatogenesis, median: 6.8-12.4 months (range 2.7-18.1 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Follicle development: Within cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: I.M., SubQ: Absorption rate is slower than the elimination rate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Mean V",
"     <sub>",
"      d",
"     </sub>",
"     : 10 L with",
"     <i>",
"      in vitro",
"     </i>",
"     fertilization/embryo transfer patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~66% to 76% in healthy female volunteers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 50 hours in healthy female volunteers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ: 24 hours in healthy female volunteers; 32 hours with",
"     <i>",
"      in vitro",
"     </i>",
"     fertilization/embryo transfer patients; 32-41 hours in healthy male volunteers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: In healthy volunteers:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: SubQ: 8-16 hours; I.M.: 25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: SubQ: 11-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Clearance: I.V.: 0.6 L/hour in healthy female volunteers",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Association of Clinical Endocrinologists, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients &minus; 2002 Update,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2002, 8(6):440-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/21/37205/abstract-text/15260010/pubmed\" id=\"15260010\" target=\"_blank\">",
"        15260010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goa KL and Wagstaff AJ, &ldquo;Follitropin Alpha in Infertility,&rdquo;",
"      <i>",
"       BioDrugs",
"      </i>",
"      , 1998, 9(3):235-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/21/37205/abstract-text/18020563/pubmed\" id=\"18020563\" target=\"_blank\">",
"        18020563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Petak SM, Nankin HR, Spark RF, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients -- 2002 Update,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2002, 8(6):440-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/21/37205/abstract-text/15260010/pubmed\" id=\"15260010\" target=\"_blank\">",
"        15260010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Williams RS, Vensel T, Sistrom CL, et al, &ldquo;Pregnancy Rates in Varying Age Groups After",
"      <i>",
"       in vitro",
"      </i>",
"      Fertilization: A Comparison of Follitropin Alfa (Gonal F) and Follitropin Beta (Follistim),&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2003, 189(2):342-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/21/37205/abstract-text/14520188/pubmed\" id=\"14520188\" target=\"_blank\">",
"        14520188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8923 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-18180375D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37205=[""].join("\n");
var outline_f36_21_37205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882602\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3888769\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882605\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882635\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882636\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13812856\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13812857\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242582\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882604\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882637\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242583\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882615\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882610\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882611\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299360\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220486\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882606\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882607\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882609\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355452\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370386\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882639\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301369\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882624\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882626\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8923\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8923|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/14/29924?source=related_link\">",
"      Follitropin alfa (recombinant human follicle stimulating hormone): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37206="Medullary sponge kidney";
var content_f36_21_37206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medullary sponge kidney",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37206/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37206/contributors\">",
"     David S Goldfarb, MD, FACP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37206/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37206/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37206/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/21/37206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21853595\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary sponge kidney is a congenital disorder characterized by malformation of the terminal collecting ducts in the pericalyceal region of the renal pyramids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This collecting duct dilatation, or ectasia, is associated with the formation of both small (microscopic) and large medullary cysts that are often diffuse but do not involve the cortex.",
"   </p>",
"   <p>",
"    Medullary sponge kidney is usually asymptomatic. The diagnosis is commonly made as an incidental finding during an imaging test performed for a different indication. Although considered benign, the associated complications of medullary sponge kidney (eg, nephrolithiasis and urinary tract infections) may rarely lead to chronic kidney disease and even renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84076586\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The changes seen in medullary sponge kidney are thought to reflect a developmental abnormality, though the underlying defect is not fully understood. The association of medullary sponge kidney with malformations affecting the kidney such as hemihypertrophy and Beckwith-Wiedemann syndrome has led to speculation that the disorder results from a disruption of the interface between the ureteral-bud and the metanephric blastema during embryonic development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for genetic transmission of medullary sponge kidney is limited. Some patients with medullary sponge kidney have mutations in the gene for glial cell-derived neurotrophic factor, a protein that is pivotal in renal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/6\">",
"     6",
"    </a>",
"    ]. Although occasional families with medullary sponge kidney appear to show autosomal dominant inheritance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1,3\">",
"     1,3",
"    </a>",
"    ], a positive family history is usually absent. Along with a benign clinical course, this helps distinguish medullary sponge kidney from two other diseases that are genetically transmitted and typically progressive, specifically autosomal dominant polycystic kidney disease and autosomal dominant interstitial kidney disease. Whether medullary sponge kidney disease is related to these disorders with respect to pathogenesis is currently not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described elsewhere, a common clinical manifestation of medullary sponge kidney is recurrent calcium phosphate and calcium oxalate stone formation. (See",
"    <a class=\"local\" href=\"#H21853656\">",
"     'Kidney stones and nephrocalcinosis'",
"    </a>",
"    below.) Several factors are thought to contribute to such formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Affected patients often have well established urinary risk factors for calcium stone formation, such as hypercalciuria, hyperuricosuria, hypocitraturia, and hyperoxaluria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1,7-9\">",
"       1,7-9",
"      </a>",
"      ]. The frequency of these abnormalities may be higher than in stone formers without medullary sponge kidney. Hypercalciuria in patients with medullary sponge kidney may, in some patients, reflect impaired calcium reabsorption by the damaged collecting tubules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"       \"Risk factors for calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with medullary sponge kidney often form apatite (calcium phosphate) concretions in the cysts, which then act as a nidus for stone formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1\">",
"       1",
"      </a>",
"      ]. Two potential mechanisms contribute to this nephrocalcinosis: stasis in the ectatic collecting ducts and cysts; and an increased urine pH, due to impaired local acidification in the terminal collecting duct. Although the urine pH may be appropriately acid (less than 5.3) if the number of affected nephrons with impaired acidification is relatively low, some patients with medullary sponge kidney have an incomplete distal renal tubular acidosis in which the urine pH remains above 5.3, even in the setting of an acid load [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1,10\">",
"       1,10",
"      </a>",
"      ]. Overt metabolic acidosis has been described but is uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853625\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of this disorder is not clear, in part because patients are often diagnosed when urologic imaging is performed for a specific indication. As an example, a diagnosis of medullary sponge kidney was made in fewer than one percent of patients undergoing intravenous urographic studies for any indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/5\">",
"     5",
"    </a>",
"    ]. Since many patients with medullary sponge kidney are asymptomatic, the true prevalence in the population is likely to be much lower.",
"   </p>",
"   <p>",
"    On the other hand, the prevalence of medullary sponge kidney is much higher in certain clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      12 to 20 percent of patients who recurrently form calcium stones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1,7,8\">",
"       1,7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      20 to 30 percent of recurrent calcium stone formers who are under the age of 20 or women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853633\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many, if not most, patients with medullary sponge kidney are asymptomatic. The disease either remains undiagnosed or is discovered incidentally with a radiographic study, such as an intravenous pyelogram (IVP) or computed tomographic (CT) urogram, performed for some other indication.",
"   </p>",
"   <p>",
"    When patients with medullary sponge kidney present with symptoms, the major clinical manifestations are kidney stones (which can cause flank pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematuria), hematuria, and urinary tract infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/5\">",
"     5",
"    </a>",
"    ]. The age at diagnosis is typically 30 to 50 years; however, the range is wide with some teenagers presenting with renal colic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853656\">",
"    <span class=\"h2\">",
"     Kidney stones and nephrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of stones and nephrocalcinosis (the deposition of calcium phosphate in the kidney) in patients with medullary sponge kidney is hard to determine, since most patients with this disorder go undiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the diagnosis is frequently made in patients being evaluated for recurrent nephrolithiasis. (See",
"    <a class=\"local\" href=\"#H21853625\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The stones in medullary sponge kidney are primarily composed of calcium phosphate and calcium oxalate. Carbonate apatite, a form of calcium phosphate, may also be present. In the presence of urinary tract infection with urease-producing organisms, struvite may be a component as well. As previously described, several factors are thought to contribute to stone formation in this setting. (See",
"    <a class=\"local\" href=\"#H84076586\">",
"     'Etiology and pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853694\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria is another common symptom in medullary sponge kidney, and its presentation is highly variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1\">",
"     1",
"    </a>",
"    ]. It can occur in the presence or absence of stones, can be associated with nephrocalcinosis, can be microscopic or gross, and can be singular or recurrent. The bleeding is typically painless unless clots lead to ureteral obstruction or is associated with nephrolithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853702\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection also occurs with increased frequency in medullary sponge kidney, especially in women. Approximately one third of women with this disorder have two or more infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/7\">",
"     7",
"    </a>",
"    ]. Stone formation and stasis in the cysts are probable contributing factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853710\">",
"    <span class=\"h2\">",
"     Decreased concentrating ability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collecting tubule dysfunction can also lead to decreased maximum concentrating ability in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. However, the defect is usually mild and does not lead to symptomatic polyuria except for occasional nocturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853718\">",
"    <span class=\"h2\">",
"     Diminished bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not uniquely observed in those with medullary sponge kidney, many patients appear to have decreased bone mineral density. One uncontrolled study demonstrated that patients with medullary sponge kidney and hypercalciuria had diminished bone mineral density (BMD); 59 percent of these patients had a T score between -1.0 and -2.5 (osteopenia) and 12 percent had a T score lower than -2.5 (osteoporosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/13\">",
"     13",
"    </a>",
"    ]. In a second study, 71 percent of patients had either osteopenia or osteoporosis, and BMD improved with potassium citrate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/13\">",
"     13",
"    </a>",
"    ]. As with other calcium stone formers with hypercalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/14\">",
"     14",
"    </a>",
"    ], there was an inverse correlation of lower BMD with higher urine calcium excretion.",
"   </p>",
"   <p>",
"    In addition to higher urine calcium excretion, two further mechanisms may contribute to decreased bone mineral density:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired acidification of the urine could result in reduced BMD, and treatment with potassium citrate is associated with improved BMD. However, impaired acidification has not been consistently demonstrated.",
"     </li>",
"     <li>",
"      An association between medullary sponge kidney and hyperparathyroidism has been observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/15\">",
"       15",
"      </a>",
"      ], but this association is inconsistent and not clearly related to stone formation or diminished BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534533394\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with medullary sponge kidney frequently undergo imaging of the genitourinary tract that is performed for another indication. The appearance varies based upon the modality. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534533515\">",
"    <span class=\"h2\">",
"     Intravenous pyelography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cystic dilatations in the kidneys of affected patients lead to the appearance on intravenous pyelography (IVP) of a \"brush\", or linear striations, radiating outward from some or all of the calyces (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53793 \" href=\"mobipreview.htm?0/27/447\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64427 \" href=\"mobipreview.htm?14/5/14431\">",
"     image 2",
"    </a>",
"    ). Enlargement of the pyramids and intraductal concretions are also often seen. Calcium stones, if present, are typically small and, almost pathognomonically, occur in clusters limited to the affected calyces (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50100 \" href=\"mobipreview.htm?18/29/18910\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76195 \" href=\"mobipreview.htm?15/54/16226\">",
"     image 4",
"    </a>",
"    ). Most affected patients have bilateral involvement, but some have involvement of only one kidney or of only some calyces.",
"   </p>",
"   <p>",
"    There are two major difficulties with the radiographic appearance of medullary sponge kidney with an IVP. First, these findings may be absent if the examination is suboptimal. In one report, for example, only 3 of 53 studies were of satisfactory quality to visualize the pericalyceal anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1\">",
"     1",
"    </a>",
"    ]. Stool and gas in the bowel often obscure the renal anatomy. Second, a more subtle homogeneous pre-calyceal \"blush\" may be seen on IVP. This may represent mild medullary sponge kidney in some cases, but a definitive radiologic diagnosis requires other features of this disorder such as cystic dilatations or intraductal calcifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of medullary sponge kidney is most likely if these cystic dilatations appear 10 minutes or later after contrast injection, provided there is no urinary obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534533522\">",
"    <span class=\"h2\">",
"     Computerized tomography (CT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-contrast CT scan can detect medullary nephrocalcinosis, suggestive of medullary sponge kidney, but this finding is seen in other disorders associated with hypercalciuria or renal stones and tubular ectasia is not as well seen as with IVP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/17\">",
"     17",
"    </a>",
"    ]. Newer techniques such as multidetector-row CT permit the creation of high-resolution three-dimensional displays that provide both cross-sectional and IVP-like images of the contrast-filled renal collecting systems, ureters, and urinary bladder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51867 \" href=\"mobipreview.htm?26/18/26912\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534533529\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although magnetic resonance imaging (MRI) might be useful if gadolinium is administered, it cannot distinguish medullary sponge kidney from autosomal dominant interstitial kidney disease. Discrimination between the two disorders could only be made on clinical grounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/19\">",
"     19",
"    </a>",
"    ]. Ultrasonography typically reveals a uniformly echogenic corticomedullary junction due to calcium deposits in the affected regions, but is considered much less specific than IVP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853726\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no current gold standard for the diagnosis of medullary sponge kidney. Previously, the diagnosis of medullary sponge kidney was made by intravenous pyelography (IVP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/5,20-22\">",
"     5,20-22",
"    </a>",
"    ]. A definitive radiologic diagnosis is provided by the finding of cystic dilations, with pooling of radiocontrast leading to a calyceal &ldquo;brush&rdquo;-like appearance, in combination with either nephrocalcinosis or nephrolithiasis. A calyceal &ldquo;brush&rdquo; by itself, while suggestive, is not definitive because it may be seen in 10 to 15 percent of IVPs, especially with low-osmolar contrast agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these findings were most commonly noted in the past when an IVP was routinely performed for the evaluation of renal colic. Currently, the preferred modality to evaluate possible nephrolithiasis is non-contrast computerized tomography (CT), which can detect medullary nephrocalcinosis but not cystic dilatations. Although suggestive of medullary sponge kidney, nephrocalcinosis is seen in other disorders associated with hypercalciuria or renal stones, and tubular ectasia is not as well seen with standard non-contrast CT as with IVP.",
"   </p>",
"   <p>",
"    Thus, only characteristic findings with either an IVP or a multidetector-row CT with contrast provide a definitive diagnosis of medullary sponge kidney. However, we would",
"    <strong>",
"     not",
"    </strong>",
"    obtain either study just to establish the diagnosis because medullary sponge kidney is usually a benign disease with no specific treatment, and failure to make the diagnosis has no adverse consequences. In addition, both IVP and multidetector-row CT are associated with a significant amount of radiation.",
"   </p>",
"   <p>",
"    Although medullary sponge kidney will continue to be detected at centers where IVP is routinely employed to evaluate patients with suspected nephrolithiasis (or if multidetector-row CT is used for a separate indication such as hematuria), the widespread availability of non-contrast CT to diagnose nephrolithiasis will diminish the frequency by which medullary sponge kidney is discovered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534533714\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient presenting with characteristic findings on an IVP or multidetector-row CT, the diagnosis of medullary sponge kidney can be made with reasonable confidence. Although patients with autosomal dominant interstitial kidney disease may have similar findings, these patients have reduced glomerular filtration rate and generally do not have stones or nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33721?source=see_link\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients with medullary sponge kidney will more commonly present with nephrocalcinosis detected as an incidental finding by an alternate imaging study. The differential diagnosis of nephrocalcinosis is broad, and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=see_link&amp;anchor=H5#H5\">",
"     \"Nephrocalcinosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with medullary sponge kidney may also present with calcium nephrolithiasis or hematuria. The evaluation of patients presenting with these findings is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21853815\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary sponge kidney has an excellent long-term prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/1\">",
"     1",
"    </a>",
"    ]. The plasma creatinine concentration remains normal in most cases. However, stone-induced episodes of obstruction can lead to transient reductions in the glomerular filtration rate, and numerous episodes of obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent infection can occasionally lead to end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To aid in identifying patients at greatest risk for complications, a grading system for medullary sponge kidney has been proposed based on a single cohort of 29 patients from one institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 1 &minus; one calyx in one kidney affected",
"     </li>",
"     <li>",
"      Grade 2 &minus; one calyx affected bilaterally",
"     </li>",
"     <li>",
"      Grade 3 &minus; more than one calyx affected in one kidney",
"     </li>",
"     <li>",
"      Grade 4 &minus; more than one calyx affected bilaterally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this cohort, higher grades were associated with more symptomatic stone episodes, more hospitalizations, and more urological interventions. This grading system has not been validated or reproduced outside of the original institution or in a larger group of patients.",
"   </p>",
"   <p>",
"    Treatment is indicated only for urinary tract infection (using appropriate antimicrobial therapy) and for recurrent stone formation. Treatment of calcium stones in patients with medullary sponge kidney, as it does in patients with idiopathic calcium stones, varies according to the specific underlying metabolic abnormality demonstrated by 24-hour urine collections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an uncontrolled, retrospective study of 97 patients with medullary sponge kidney, the predominant risk factors for nephrolithiasis were hypercalciuria and hypocitraturia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37206/abstract/24\">",
"     24",
"    </a>",
"    ]. Potassium citrate therapy (mean dose of 30",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    for an average of 6.5 years was associated with a reduction in stone formation rate from 0.58 stones per patient per year to 0.10 stones per patient per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84076897\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medullary sponge kidney is a relatively common congenital disorder that is characterized by malformation of the terminal collecting ducts in the pericalyceal region of the renal pyramids. (See",
"      <a class=\"local\" href=\"#H21853595\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The changes seen in medullary sponge kidney are thought to reflect a developmental abnormality, though the underlying defect is not known. Although occasionally familial, there is currently little evidence for genetic transmission of medullary sponge kidney and there are no known responsible genes. (See",
"      <a class=\"local\" href=\"#H84076586\">",
"       'Etiology and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The true prevalence of medullary sponge kidney is likely less than one percent in the population, but is much more common in patients with recurrent calcium nephrolithiasis, particularly those under the age of 20 years and women. (See",
"      <a class=\"local\" href=\"#H21853625\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many, if not most, patients with medullary sponge kidney are asymptomatic. When patients with medullary sponge kidney do present with symptoms, the major clinical manifestations are kidney stones (which can cause flank pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematuria), hematuria, and urinary tract infections. (See",
"      <a class=\"local\" href=\"#H21853633\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with medullary sponge kidney often have well established urinary risk factors for calcium stone formation, such as hypercalciuria, hyperuricosuria, hypocitraturia, and hyperoxaluria. In addition, apatite (calcium phosphate) concretions form in the cysts, which then act as a nidus for stone formation. (See",
"      <a class=\"local\" href=\"#H21853656\">",
"       'Kidney stones and nephrocalcinosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematuria&nbsp;can occur in the presence or absence of stones, can be associated with nephrocalcinosis, can be microscopic or gross, and can occur once or many times. (See",
"      <a class=\"local\" href=\"#H21853694\">",
"       'Hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary tract infection also occurs with increased frequency in medullary sponge kidney, especially in women. (See",
"      <a class=\"local\" href=\"#H21853702\">",
"       'Urinary tract infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medullary sponge kidney usually remains undiagnosed or is discovered incidentally with a radiographic study, such as an intravenous pyelogram (IVP) or computed tomographic (CT) urogram, performed for some other indication. (See",
"      <a class=\"local\" href=\"#H21853726\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of medullary sponge kidney can most readily be made by IVP. However, because it has largely been supplanted by non-contrast CT for diagnosis and management of renal colic, IVP is uncommonly performed. (See",
"      <a class=\"local\" href=\"#H21853726\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medullary sponge kidney has an excellent long-term prognosis. The plasma creatinine concentration remains normal in most cases. However, stone-induced episodes of obstruction can lead to acute kidney injury, and numerous episodes of obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent infection can occasionally lead to chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H21853815\">",
"       'Prognosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is indicated only for urinary tract infection (using appropriate antimicrobial therapy) and for recurrent stone formation. (See",
"      <a class=\"local\" href=\"#H21853815\">",
"       'Prognosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hilderbrandt, F, Sayer, JA, Jungers, P, et al. Nephronophthisis-Medullary Cystic and Medullary Sponge Kidney Disease. In: Diseases of the Kidney &amp; Urinary Tract, 8th ed, Schrier, RW (Ed), Lippinicott, Williams &amp; Wilkins, Philadelphia 2007. p. 478.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/2\">",
"      MORRIS RC, YAMAUCHI H, PALUBINSKAS AJ, HOWENSTINE J. MEDULLARY SPONGE KIDNEY. Am J Med 1965; 38:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/3\">",
"      Goldman SH, Walker SR, Merigan TC Jr, et al. Hereditary occurrence of cystic disease of the renal medulla. N Engl J Med 1966; 274:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/4\">",
"      Jungers P, Joly D, Barbey F, et al. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004; 44:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/5\">",
"      Gambaro G, Feltrin GP, Lupo A, et al. Medullary sponge kidney (Lenarduzzi-Cacchi-Ricci disease): a Padua Medical School discovery in the 1930s. Kidney Int 2006; 69:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/6\">",
"      Torregrossa R, Anglani F, Fabris A, et al. Identification of GDNF gene sequence variations in patients with medullary sponge kidney disease. Clin J Am Soc Nephrol 2010; 5:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/7\">",
"      Parks JH, Coe FL, Strauss AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med 1982; 306:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/8\">",
"      Yagisawa T, Kobayashi C, Hayashi T, et al. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 2001; 37:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/9\">",
"      O'Neill M, Breslau NA, Pak CY. Metabolic evaluation of nephrolithiasis in patients with medullary sponge kidney. JAMA 1981; 245:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/10\">",
"      Higashihara E, Nutahara K, Tago K, et al. Medullary sponge kidney and renal acidification defect. Kidney Int 1984; 25:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/11\">",
"      Carboni I, Andreucci E, Caruso MR, et al. Medullary sponge kidney associated with primary distal renal tubular acidosis and mutations of the H+-ATPase genes. Nephrol Dial Transplant 2009; 24:2734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/12\">",
"      Baggio B, Priante G, Brunati AM, et al. Specific modulatory effect of arachidonic acid on human red blood cell oxalate transport: clinical implications in calcium oxalate nephrolithiasis. J Am Soc Nephrol 1999; 10 Suppl 14:S381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/13\">",
"      Fabris A, Bernich P, Abaterusso C, et al. Bone disease in medullary sponge kidney and effect of potassium citrate treatment. Clin J Am Soc Nephrol 2009; 4:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/14\">",
"      Asplin JR, Donahue S, Kinder J, Coe FL. Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int 2006; 70:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/15\">",
"      Maschio G, Tessitore N, D'Angelo A, et al. Medullary sponge kidney and hyperparathyroidism--a puzzling association. Am J Nephrol 1982; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/16\">",
"      Forster JA, Taylor J, Browning AJ, Biyani CS. A review of the natural progression of medullary sponge kidney and a novel grading system based on intravenous urography findings. Urol Int 2007; 78:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/17\">",
"      Ginalski JM, Schnyder P, Portmann L, Jaeger P. Medullary sponge kidney on axial computed tomography: comparison with excretory urography. Eur J Radiol 1991; 12:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/18\">",
"      Maw AM, Megibow AJ, Grasso M, Goldfarb DS. Diagnosis of medullary sponge kidney by computed tomographic urography. Am J Kidney Dis 2007; 50:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/19\">",
"      Meier P, Farres MT, Mougenot B, et al. Imaging medullary cystic kidney disease with magnetic resonance. Am J Kidney Dis 2003; 42:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/20\">",
"      Levine E, Hartman DS, Meilstrup JW, et al. Current concepts and controversies in imaging of renal cystic diseases. Urol Clin North Am 1997; 24:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/21\">",
"      Katabathina VS, Kota G, Dasyam AK, et al. Adult renal cystic disease: a genetic, biological, and developmental primer. Radiographics 2010; 30:1509.",
"     </a>",
"    </li>",
"    <li>",
"     Lippert, MC. Medullary Sponge Kidney in: Adult and Pediatric Urology, Fourth Edition. Gillenwater, JY, Grayhack JT, Howards, SS, Mitchell, ME, (Eds), Lippincott, Williams and Wilkins, Philadelphia, 2003. p. 863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/23\">",
"      Ohlson L. Normal collecting ducts: visualization at urography. Radiology 1989; 170:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37206/abstract/24\">",
"      Fabris A, Lupo A, Bernich P, et al. Long-term treatment with potassium citrate and renal stones in medullary sponge kidney. Clin J Am Soc Nephrol 2010; 5:1663.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7369 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-115.25.216.6-89DD65BA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37206=[""].join("\n");
var outline_f36_21_37206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H84076897\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21853595\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84076586\">",
"      ETIOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21853625\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21853633\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21853656\">",
"      Kidney stones and nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21853694\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21853702\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21853710\">",
"      Decreased concentrating ability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21853718\">",
"      Diminished bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H534533394\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H534533515\">",
"      Intravenous pyelography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H534533522\">",
"      Computerized tomography (CT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H534533529\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21853726\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H534533714\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21853815\">",
"      PROGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84076897\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7369|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/27/447\" title=\"diagnostic image 1\">",
"      Intravenous pyelogram in medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/5/14431\" title=\"diagnostic image 2\">",
"      Calyceal brush in medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/29/18910\" title=\"diagnostic image 3\">",
"      Calcifications in sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/54/16226\" title=\"diagnostic image 4\">",
"      Medullary sponge kidney CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/18/26912\" title=\"diagnostic image 5\">",
"      Medullary sponge kidney using multidetector row CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17081?source=related_link\">",
"      Nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37207="Invasive hemodynamic tracing HCM with LVOT obstruction 2";
var content_f36_21_37207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    HCM with left ventricular outflow tract obstruction at rest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown from top to bottom are four surface ECG leads, and the left ventricular (LV) and aortic (Ao) pressure tracings from a patient with hypertrophic cardiomyopathy. The maximum LV systolic pressure is 230 mmHg; the Ao pressure, measured simultaneously with the maximum LV pressure, is 85 mmHg, thereby resulting in a LV outflow gradient of 145 mmHg. The LV systolic pressure varies by 20 to 30 mmHg with each beat (alternans), a finding occasionally found in HCM. The aortic pulse pressure is narrow (25 mmHg) and the pressure tracing reveals the spike-and-dome configuration of LV outflow obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lameh Fananapazir, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37207=[""].join("\n");
var outline_f36_21_37207=null;
var title_f36_21_37208="Chron pancreatitis H and E";
var content_f36_21_37208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    H and E stained section of pancreas from a patient with chronic pancreatitis. Pancreatic biopsy showing extensive fibrosis, chronic inflammation, residual ductal structures, and a residual islet. There is no acinar tissue remaining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Larry Brown, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37208=[""].join("\n");
var outline_f36_21_37208=null;
var title_f36_21_37209="Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease";
var content_f36_21_37209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Robert L Coleman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Paul Sabbatini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37209/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/21/37209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1846264236\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics, behavior, and in many cases share basic biology. As such, these are often considered collectively and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three primary sites under the heading EOC.",
"   </p>",
"   <p>",
"    Despite initial therapy (usually consisting of surgical cytoreduction and platinum-taxane combination therapy), the majority of women with advanced stage ovarian cancer will relapse and require additional treatment. Taking into account the frequency of each stage of disease and its projected relapse rate, the overall likelihood of relapse after initial therapy for all stages of disease for women with EOC is 62 percent; it is 80 to 85 percent for women who present with stage III or IV disease. The likelihood for recurrence depends on many factors including distribution of disease at initial presentation, success of initial surgical cytoreduction, rapidity of CA125 resolution, and treatment response after primary therapy. However, a predictive marker for recurrence has not been prospectively verified.",
"   </p>",
"   <p>",
"    The management of relapsed disease is frequently stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H760206841#H760206841\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Treatment of recurrent disease'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a PFI of six months or longer are considered to have chemotherapy-sensitive disease (often also termed &ldquo;platinum sensitive&rdquo;). The management of these patients is discussed here.",
"     </li>",
"     <li>",
"      Patients with a PFI of less than six months are considered to have chemotherapy-resistant disease (often also termed &ldquo;platinum-resistant&rdquo;). Of this group, those patients who progress while on platinum-based therapy are often referred to as having &ldquo;platinum-refractory&rdquo; disease. The management of these patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial diagnosis and management of EOC, the surgical treatment of recurrent EOC, and an overview of angiogenesis inhibitors in EOC are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28070?source=see_link\">",
"     \"Surgery for recurrent epithelial ovarian cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=see_link&amp;anchor=H14635776#H14635776\">",
"     \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Recurrent disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1846264320\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients who relapse with EOC determined by symptoms or radiographic evidence of disease progression should be offered chemotherapy. Patients with chemotherapy-sensitive recurrent EOC frequently achieve responses to re-treatment using combination therapy. The degree of sensitivity is imperfectly assessed, but many clinical trials have shown that the PFI is a major predictor of response to therapy, both for platinum and non-platinum agents, and is also proportionately related to progression-free and overall survival. Therefore, it is not uncommon to see PFI as a stratification factor for comparative clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H760206841#H760206841\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Treatment of recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with platinum-sensitive recurrent EOC should be considered for both secondary cytoreduction and second-line chemotherapy. The use of second-line chemotherapy is discussed in the following sections. However, the platinum-free interval not only predicts response to retreatment with platinum, but also has been shown to predict favorable outcomes for women who undergo secondary cytoreduction. Secondary cytoreduction is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28070?source=see_link\">",
"     \"Surgery for recurrent epithelial ovarian cancer\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4501538\">",
"    <span class=\"h2\">",
"     Selection of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse six months or longer after receiving initial therapy with a platinum-based treatment are more likely to respond to retreatment with a chemotherapy regimen that contains a platinum agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ). In general, combination therapy is preferred to single agent therapy because in most cases it is associated with superior objective response and progression-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. However, single agent therapy may be appropriate for medically frail patients or those with lingering toxicities from prior therapy. While the ideal platinum-based combination therapy is not known and choices depend on physician and patient preferences, options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      (Area under the curve [AUC] 5) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      IV every three weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/9\">",
"       9",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_table graphicRef65626 \" href=\"mobipreview.htm?6/57/7070\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      (AUC 4) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) IV every three weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      (AUC 5) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (PLD, 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      IV every four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and PLD has the advantages of ease of scheduling (every four weeks), lack of alopecia, low risk of neurologic toxicity, and low risk of carboplatin allergic reactions. However, the 2011 drug shortage of PLD has become an issue in the care of patients with recurrent EOC. In addition to alternative regimens listed above, several other choices are used in clinical practice, such as the substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or the administration of dose-dense paclitaxel, in combination with platinum. The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (800 to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (30 to 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    administered on an every other week schedule has been used predominately in patients with platinum-resistant disease, but in our experience it is an effective alternative to carboplatin plus gemcitabine when patients experience repeat delays due to myelosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both high dose chemotherapy with autologous hematopoietic cell transplantation and the use of intraperitoneal chemotherapy have been evaluated in women with recurrent EOC. However, there is no evidence that either of these approaches improves survival outcomes compared to standard IV chemotherapy. These approaches are investigational and should not be considered standard of care options. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H250842013#H250842013\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1846264327\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination chemotherapy in the treatment of women with platinum sensitive EOC was evaluated in multiple phase III studies. In general, platinum based combination therapy demonstrates consistent improvements in response and progression-free survival with overall response rates (complete plus partial response rates, ORR) from 50 to 60 percent. Multiple combinations are acceptable; however, the ideal platinum-based combination is not known.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      - In parallel phase III trials conducted by the International Collaboration on Ovarian Neoplasms (ICON-4) and the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR-2.2), 802 women were treated with either single agent platinum (carboplatin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) or a non-taxane containing platinum combination (eg, cisplatin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , CAP), or paclitaxel plus a platinum agent (with 80 percent receiving carboplatin) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/9\">",
"       9",
"      </a>",
"      ]. With a median follow-up of 42 months, compared to use of a non-paclitaxel containing therapy, treatment with paclitaxel plus a platinum agent resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significant survival benefit (hazard ratio [HR] 0.82, 95% CI 0.69-0.97)",
"     </li>",
"     <li>",
"      An absolute two-year survival benefit of 7 percent (57 versus 50 percent)",
"     </li>",
"     <li>",
"      A five month improvement in median survival (29 versus 24 months)",
"     </li>",
"     <li>",
"      Higher incidence of grade 2 to 4 neurologic effects (20 versus 1 percent) and alopecia (86 versus 25 percent)",
"     </li>",
"     <li>",
"      A lower rate of myelosuppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is the only study to date that has documented an improvement in overall survival, but has been criticized due to the high proportion of taxane-na&iuml;ve patients entering into the trial and the nearly 30 percent of patients in the control arm who were never treated with a taxane as part of initial or subsequent therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      - A phase III study conducted by the Gynecologic Cancer Intergroup (GCIG) enrolled 356 women and randomly assigned therapy with 21-day cycles of carboplatin alone or carboplatin plus gemcitabine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/10\">",
"       10",
"      </a>",
"      ]. Compared to single agent carboplatin, combined therapy resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A statistically significantly higher overall response rate (47 versus 31 percent)",
"     </li>",
"     <li>",
"      An increase in the median progression-free survival (PFS, 8.6 versus 5.8 months)",
"     </li>",
"     <li>",
"      No improvement in the median overall survival (18 versus 17.3 months, respectively)",
"     </li>",
"     <li>",
"      Significant increase in serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      hematologic toxicity, including neutropenia (71 versus 12 percent) and thrombocytopenia (35 versus 11 percent)",
"     </li>",
"     <li>",
"      Increased use of granulocyte colony stimulating factors (G-CSF) (24 versus 10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      <strong>",
"       plus PLD",
"      </strong>",
"      - The phase III Caelyx&reg; in platinum-sensitive EOC (CALYPSO) trial is the largest phase III in the recurrent setting to be completed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. It was designed to test the hypothesis that PLD plus carboplatin was not inferior to carboplatin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      . The study enrolled 976 women and randomly assigned treatment with carboplatin and either paclitaxel or PLD. With a median follow-up of 22 months, compared to carboplatin plus paclitaxel, PLD plus carboplatin resulted in [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/13,15\">",
"       13,15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significant improvement in median PFS (11.3 versus 9.4 months).",
"     </li>",
"     <li>",
"      Fewer cases of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (35 versus 46 percent), but more severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thrombocytopenia (16 versus 6 percent).",
"     </li>",
"     <li>",
"      More episodes of mild (grade 2) nausea (35 versus 24 percent), vomiting (23 versus 16 percent), hand-foot syndrome (12 versus 2 percent), and mucositis (14 versus 7 percent), but less mild (grade 2)",
"      <span class=\"nowrap\">",
"       myalgias/arthralgias",
"      </span>",
"      (4 versus 19 percent), neuropathy (5 versus 27 percent).",
"     </li>",
"     <li>",
"      Substantially fewer episodes of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      hypersensitivity reactions (16 versus 33 percent).",
"     </li>",
"     <li>",
"      With a median follow-up of 40 months, OS was equivalent between the treatment arms (30.7 with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus PLD versus 33.0 months with carboplatin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [HR 0.99, 95% CI 0.85-1.16]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data support the superiority of a platinum-based combination compared to single agent platinum for initial treatment of relapsed disease. When platinum cannot be given to patients with platinum sensitive disease (due to previous hypersensitivity or other comorbidities), single non platinum agents are often used. Several studies have proposed doublets of non platinum agents but no clear consensus exists as to whether they are superior to single agents in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. As an example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       Trabectedin",
"      </a>",
"      <strong>",
"       plus PLD",
"      </strong>",
"      &ndash; Trabectedin is a novel marine-derived alkaloid that kills cells by poisoning the DNA nucleotide excision repair machinery. It is approved for use in ovarian cancer in Europe and other countries, but not in the United States. The approval outside of the US was based on the OVA-301 study of 672 women that were randomly assigned treatment with PLD (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every four weeks) or PLD (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus trabectedin (1.1",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over three hours) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/19\">",
"       19",
"      </a>",
"      ]. Compared to single agent PLD, the combination of trabectedin plus PLD resulted in the following outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/17,20\">",
"       17,20",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significant reduction in the risk of progression in women with platinum-sensitive disease (median, 9.2 versus 7.5 months, HR for disease progression, 0.73, 95% CI 0.56-0.95) but not in platinum-resistant disease (PFS in both arms was 4 months).",
"     </li>",
"     <li>",
"      A significant improvement in the overall response rate in the platinum-sensitive cohort (ORR, 35 versus 22 percent).",
"     </li>",
"     <li>",
"      No difference in OS between the arms (22.4 versus 19.5 months) nor in the platinum-sensitive cohort (27.0 versus 24.3 months, HR for death, 0.85, 95% CI: 0.70-1.03) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overall, treatment was well tolerated; neutropenia and grade 3 or 4 transaminase elevation were more common in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       trabectedin",
"      </a>",
"      group, while hand-foot syndrome and mucositis were less common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1846264342\">",
"    <span class=\"h3\">",
"     Is there a role for bevacizumab?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiogenesis inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is being studied as a treatment option for platinum-sensitive recurrent EOC in combination with chemotherapy. Results of only one phase III trial are available. While multiple other phase II studies have evaluated bevacizumab in combination therapy in recurrent EOC, many have not restricted eligibility to women only with platinum-sensitive EOC. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=see_link&amp;anchor=H14635776#H14635776\">",
"     \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the phase III OCEANS study, 484 women with platinum-sensitive EOC were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (AUC 4 on day 1) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 8) with cycles repeated every 21 days with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day 1 every three weeks concurrent with chemotherapy for 10 cycles maximum, followed by bevacizumab alone until disease progression or toxicity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Bevacizumab with chemotherapy resulted in the following when compared with chemotherapy plus placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in progression-free survival (12 versus 8 months, hazard ratio [HR] 0.48, 95% CI 0.39-0.61).",
"     </li>",
"     <li>",
"      Higher objective response rate (79 versus 57 percent, p&lt;.001).",
"     </li>",
"     <li>",
"      Higher rate of treatment discontinuation for adverse events (23 versus 5 percent) including higher rates of serious hypertension (17 versus &lt;1 percent), proteinuria &gt;grade 3 (9 versus 1 percent), and non-central nervous system bleeding (6 versus 1 percent). There were no cases of gastrointestinal perforation reported during therapy.",
"     </li>",
"     <li>",
"      With a median follow-up of 35 months, similar overall survival (33 versus 35 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for EOC is evolving. In addition to OCEANS, the Gynecologic Oncology Group 213 trial (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00565851\">",
"     GOG 213",
"    </a>",
"    ) is a randomized study for women with recurrent platinum-sensitive EOC evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    with or without bevacizumab. The primary endpoint of this trial is OS. We await further follow-up on these and other trials to better define when and how to use bevacizumab.",
"   </p>",
"   <p>",
"    For patients with recurrent platinum-sensitive EOC, we prefer to use combination chemotherapy alone rather than the use of combination chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    at this time. However, others prefer to use bevacizumab,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224704057\">",
"    <span class=\"h2\">",
"     Single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platinum-based combination chemotherapy is the preferred treatment for most patients with platinum-sensitive relapsed EOC. A subset of women may not be candidates for retreatment with platinum agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) either due to a history of a hypersensitivity reaction or persistent toxicities from first line therapy. Such patients may be candidates for single agent therapy with other drugs. Among the most active agents for women with platinum-sensitive recurrent EOC are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      &ndash; A Gynecologic Oncology Group (GOG) study involved 82 patients who were treated with etoposide (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      given orally for 21 days of a 28-day cycle). Among the group with platinum-sensitive EOC (n=41), the overall response rate (ORR) was 34 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/23\">",
"       23",
"      </a>",
"      ]. Serious toxicities (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      are predominantly hematologic (neutropenia, thrombocytopenia, and leukopenia). There is also a 2 percent risk of secondary leukemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       Topotecan",
"      </a>",
"      &ndash; In a phase III study that included 474 women with recurrent EOC, all patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (PLD) or topotecan (1.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      for five days every 21 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/24\">",
"       24",
"      </a>",
"      ]. Among platinum-sensitive patients treated with topotecan, the ORR was 29 percent. An alternative weekly schedule (4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) was evaluated in a cohort of 43 patients and resulted in a 24 percent ORR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/25\">",
"       25",
"      </a>",
"      ]. Serious toxicity is predominantly hematologic. Several studies have suggested lower starting doses (ie, 1.0 to 1.25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for five days every 21 days) to ameliorate hematologic toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"      &ndash; In the randomized trial of PLD versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      discussed above, PLD (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 28 days) resulted in an ORR of 28 percent among platinum-sensitive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/24\">",
"       24",
"      </a>",
"      ]. It should be noted that while the FDA-approved dose is 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      most clinicians start at a lower dose (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      to reduce the risk of skin toxicity",
"      <sup>",
"      </sup>",
"      while maintaining the activity of this agent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      - A phase III trial that included 153 patients randomly assigned treatment with PLD or gemcitabine (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15 of a 28 day cycle) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/28\">",
"       28",
"      </a>",
"      ]. Treatment with gemcitabine resulted in an ORR of 29 percent. Neutropenia is a common toxicity of this agent.",
"     </li>",
"     <li>",
"      <strong>",
"       Nanoparticle albumin bound (nAb)",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      - Nanoparticle albumin bound (nAb) paclitaxel (260",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 every three weeks or 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 15 on a 28-day schedule) was evaluated in a cohort of 47 women with recurrent EOC and resulted in an ORR of 64 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/29\">",
"       29",
"      </a>",
"      ]. nAb Paclitaxel may also be given weekly (80 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 15 on a 28-day schedule) as has been studied in the platinum-resistant setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/30\">",
"       30",
"      </a>",
"      ]. The most common toxicities are neutropenia and neuropathy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       Trabectedin",
"      </a>",
"      &ndash; Although it is not available in the United States, trabectedin was approved in both Europe and Canada for treatment of relapsed EOC. Although activity has been seen in women previously treated with platinum and taxanes, it has shown most of its activity in women who relapse with platinum-sensitive disease, as demonstrated in two phase II trials:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a multi-institutional European study, 59 women received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       trabectedin",
"      </a>",
"      (1300",
"      <span class=\"nowrap\">",
"       mcg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over three hours every three weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/31\">",
"       31",
"      </a>",
"      ]. Among 29 women with platinum-sensitive disease, the overall response rate (ORR) was 43 percent; in the 30 women with platinum-resistant disease, only two responses were recorded (seven percent).",
"     </li>",
"     <li>",
"      In a separate study, 141 women (62 platinum-sensitive, 79 platinum-resistant) were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/52/41798?source=see_link\">",
"       trabectedin",
"      </a>",
"      on a four week cycle (580",
"      <span class=\"nowrap\">",
"       mcg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over three hours weekly for three weeks followed by one week off) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/32\">",
"       32",
"      </a>",
"      ]. Among women with platinum-sensitive disease, the ORR was 29 percent with a median PFS of five months. Among those with platinum-resistant disease, the ORR was six percent with a median progression free survival of two months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468387732\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for recurrent EOC is not curative. However, for women who achieve a response or remission to platinum-based retreatment, the durability of the second remission is an important question.",
"   </p>",
"   <p>",
"    Although the data on prognosis is limited, in a study of 125 women who achieved a response to second-line platinum-based therapy, only three percent experienced a duration that was longer than the initial platinum free interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/33\">",
"     33",
"    </a>",
"    ]. In this series, treatment was often discontinued after six cycles in responding patients, raising the question of whether a maintenance treatment would help improve the duration of second (or later) response. (See",
"    <a class=\"local\" href=\"#H4501699\">",
"     'Is there a role for maintenance?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468386265\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23567221\">",
"    <span class=\"h2\">",
"     Recurrence based on CA-125 only",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ovarian cancer may be followed serially with the serum tumor marker, CA-125. In some cases, patients with an elevated CA-125 may be defined as having disease progression (sometimes referred to as serologic progression), even in the absence of clinical symptoms or radiologic findings. For these patients, we recommend surveillance rather than chemotherapy based on the results of a randomized trial that showed there was no benefit in overall survival to early compared to delayed treatment (ie, treatment initiated based on objective evidence of disease progression). This trial is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are only low quality data, we suggest the administration of endocrine therapy in patients with relapse by CA-125 alone because they appear to have some activity and are less toxic than chemotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The activity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      was demonstrated in GOG 198, which enrolled 139 patients and randomly assigned them to treatment with tamoxifen (20 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (100 mg daily with weekly dose escalation to a maximum dose of 400 mg daily). Tamoxifen resulted in a median PFS of three months and median OS 33 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/34\">",
"       34",
"      </a>",
"      ]. Of note, thalidomide resulted in a 4.5 and 24 month median PFS and OS, respectively.",
"     </li>",
"     <li>",
"      In a separate study of patients with estrogen receptor-positive ovarian cancer, 11 of 42 patients (26 percent) treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      (2.5 mg daily) had a PFS of six months or longer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23567167\">",
"    <span class=\"h2\">",
"     Genome wide tumor analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individualized molecular tumor profiling holds the promise of enabling personalized selection of molecularly targeted treatment based on the specific genotype identified. Several platforms are available including the Caris Target Now&trade; and SNaPshot&trade; technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, these assays require further evaluation to determine the appropriate use of genome wide analysis in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111338810\">",
"    <span class=\"h2\">",
"     In vitro chemosensitivity and resistance assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro assays of chemosensitivity or resistance such as the Chemo-FX&reg; assay (Precision) or the Oncotech Extreme Drug Resistance (EDR)&reg; assay (Exiqon Diagnostics) have been developed as a method to select the optimal chemotherapy regimen (sensitivity assays) or identify those agents least likely to be effective (resistance assays) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In our view, utility and cost benefits of in vitro chemosensitivity and chemoresistance assays have not been clearly demonstrated, and prospective validation is required prior to routine clinical adoption. However, others disagree, and use these assays to help in the selection of chemotherapy in patients with relapsed EOC. The role of these assays in EOC is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H250841395#H250841395\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'In vitro chemosensitivity and resistance assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224704477\">",
"    <span class=\"h2\">",
"     Retreatment with carboplatin and risk of hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (as a single agent or in combination) as a second or greater-line treatment are at risk for a hypersensitivity reaction. However, this does not necessarily exclude them as candidates for retreatment. Several protocols for carboplatin desensitization are available to help guide the treatment of women at risk or who have had a platinum allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. This topic is covered in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H21#H21\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Platinum drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4501699\">",
"    <span class=\"h2\">",
"     Is there a role for maintenance?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts at prolonging the second remission have been the subject of clinical trials, such as the OCEANS study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    maintenance described above. (See",
"    <a class=\"local\" href=\"#H1846264342\">",
"     'Is there a role for bevacizumab?'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other agents are being tested as a maintenance therapy in recurrent EOC. In one trial, 296 women with platinum-sensitive high-grade serous recurrent ovarian cancer who achieved a response to their most recent treatment were randomly assigned to treatment with the poly-ADP ribose phosphorylase (PARP) inhibitor olaparib (400 mg orally twice a day) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients had received a median of three prior regimens with approximately 60 percent in each arm having a platinum-free interval of &gt;12 months. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Olaparib resulted in a significant improvement in progression-free survival compared with placebo (8 versus 5 months, hazard ratio [HR] for progression or death 0.35, 95% CI 0.25-0.49), but interim analysis found no overall survival benefit (30 months in both, HR 0.94, 95% CI 0.63-1.39).",
"     </li>",
"     <li>",
"      Olaparib was associated with a low rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity. Adverse events (any grade) more commonly reported in the olaparib group than in the placebo group included nausea (68 versus 35 percent), fatigue (49 versus 38 percent), vomiting (32 versus 14 percent), and anemia (17 versus 5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468387753\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the best treatment is enrollment in a well designed clinical trial. Some agents in ongoing studies are reviewed here.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Farletuzumab",
"      </strong>",
"      - Farletuzumab is a humanized monoclonal antibody to the folate receptor &alpha;. The target is overexpressed in many solid tumors, including 90 percent of ovarian cancers. The exact mechanism of action for farletuzumab is not well known but it has been shown to block lyn kinase phosphorylation and induces cytotoxicity via ADCC and CDC processes. Preliminary results of a phase II open-label study in which 44 patients with platinum-sensitive EOC received either single-agent farletuzumab or, if symptomatic, a combination arm of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and farletuzumab were reported at the 2009 joint Congress of the European Cancer Organisation (ECCO) and the European Society for Medical Oncology (ESMO) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/44\">",
"       44",
"      </a>",
"      ]. The overall response was 70 percent with a median PFS of 10.9 months. A phase III, placebo-controlled trial is randomizing women with measurable platinum-sensitive recurrent ovarian cancer to paclitaxel and carboplatin with or without farletuzumab.",
"     </li>",
"     <li>",
"      <strong>",
"       Iniparib",
"      </strong>",
"      - Iniparib is an irreversible poly ADP-ribose phosphorylase (PARP) inhibitor with potentially other cytotoxic actions. In a preliminary report presented at the 2011 American Society of Clinical Oncology (ASCO) annual meeting, iniparib in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      produced a 65 percent response rate among 41 women with platinum-sensitive EOC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/45\">",
"       45",
"      </a>",
"      ]. The predominant toxicity was hematologic and the rate of hypersensitivity reactions to carboplatin was 29 percent. The median progression free survival was 9.5 months.",
"     </li>",
"     <li>",
"      <strong>",
"       Olaparib",
"      </strong>",
"      - In addition to its evaluation as a single agent, olaparib has been evaluated in combination with chemotherapy. At the 2012 ASCO Annual Meeting, the preliminary results of a randomized phase II study involving 162 patients were reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients were assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (AUC=6) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six cycles (repeated every three weeks) with or without olaparib (200 mg twice daily), followed by observation or maintenance olaparib until progression. Incorporation of olaparib to chemotherapy resulted in a significant benefit in PFS compared to chemotherapy alone (median, 12 versus 10 months, HR 0.51, 95% CI 0.34-0.77). Overall survival data were not presented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16216188\">",
"    <span class=\"h2\">",
"     Heated intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of heated IP chemotherapy (HIPEC) is indicated for mucinous carcinomas, such as appendiceal carcinoma and pseudomyxoma peritonei. Given the tendency of recurrent ovarian cancer to present as abdominal disease, there is growing interest in the use of heated IP chemotherapy (HIPEC) for women with recurrent EOC following surgical cytoreduction. However, we consider HIPEC an investigational modality for the treatment of patients with platinum-sensitive recurrent EOC.",
"   </p>",
"   <p>",
"    There are limited data evaluating the role of HIPEC for treating recurrent EOC. The largest series involved 246 patients (184 with platinum-sensitive recurrent EOC), 92 percent of whom underwent an optimal surgical cytoreduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37209/abstract/47\">",
"     47",
"    </a>",
"    ]. HIPEC treatment resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12 percent incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      complications including leukopenia (three percent), intra-abdominal hemorrhage (two percent), and postoperative complications (five percent) including one postoperative death due to an anastomotic leak resulting in peritonitis and acute renal failure. &nbsp;",
"     </li>",
"     <li>",
"      Median overall survival of 49 months; for platinum-sensitive patients, it was 52 months. The median five-year overall survival rate for the entire cohort was 35 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data illustrate the risks and the potential benefits associated with HIPEC for recurrent EOC. A",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT01376752\">",
"     randomized trial of HIPEC in recurrent EOC",
"    </a>",
"    is underway. Until more data are available, we do not administer HIPEC treatment for recurrent EOC outside of a clinical trial. The administration of HIPEC in the treatment of appendiceal carcinoma and pseudomyxoma peritonei is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1846265641\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior and are referred to as epithelial ovarian cancer (EOC). EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States.",
"     </li>",
"     <li>",
"      Patients with platinum-sensitive recurrent EOC should be considered for both secondary cytoreduction and second-line chemotherapy. The platinum free interval not only predicts response to retreatment with platinum, but has been shown to predict favorable outcomes for women who undergo secondary cytoreduction. Secondary cytoreduction is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28070?source=see_link\">",
"       \"Surgery for recurrent epithelial ovarian cancer\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      For women who experience a recurrence, the selection of therapy is commonly based upon whether women are \"sensitive\" or \"resistant\" to platinum-based treatment. Patients who respond to initial platinum-based therapy and have a significant relapse-free interval (more than six months) have a high probability of responding again to platinum-based treatment at the time of relapse. These patients are termed chemotherapy-sensitive. Women who progress on or relapse within six months of completion of prior platinum-based therapy are considered chemotherapy-resistant. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H760206841#H760206841\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Treatment of recurrent disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women who relapse solely by CA-125 (with no evidence of disease on imaging and who are asymptomatic), we recommend surveillance (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who are not comfortable with surveillance, we suggest endocrine therapy rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We reserve chemotherapy or other treatments for women who develop signs or symptoms related to recurrent EOC, or for those with significant growth on radiographic imaging in anticipation of preventing the onset of imminent symptoms. (See",
"      <a class=\"local\" href=\"#H23567221\">",
"       'Recurrence based on CA-125 only'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H32#H32\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with recurrent platinum-sensitive EOC, we suggest treatment with a platinum-based combination rather than a non-platinum-based regimen or single agent therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While alternative combinations are reasonable, our preferred combination is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      because of the ease of scheduling (every four weeks) and the manageable toxicity profile. An alternative regimen such as the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      and carboplatin is a reasonable choice. (See",
"      <a class=\"local\" href=\"#H1846264327\">",
"       'Combination therapy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For patients with recurrent platinum-sensitive EOC, we suggest the use of combination chemotherapy alone rather than the use of combination chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"local\" href=\"#H1846264342\">",
"       'Is there a role for bevacizumab?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are not candidates for treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -based combinations, carboplatin as a single agent or one of the agents discussed above is reasonable. (See",
"      <a class=\"local\" href=\"#H1224704057\">",
"       'Single agent therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with platinum-sensitive EOC who are at risk for or who have had an allergic reaction to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , options include carboplatin re-treatment using a desensitization protocol versus proceeding with a non platinum agent as a reasonable alternative. A choice between them depends on patient and provider preferences. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H21#H21\">",
"       \"Infusion reactions to systemic chemotherapy\", section on 'Platinum drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/1\">",
"      Cant&ugrave; MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/2\">",
"      Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/3\">",
"      Zanaboni F, Scarfone G, Presti M, et al. Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 1991; 43:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/4\">",
"      Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 2007; 18:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/5\">",
"      van der Burg ME, Hoff AM, van Lent M, et al. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 1991; 27:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/6\">",
"      Weiss G, Green S, Alberts DS, et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur J Cancer 1991; 27:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/7\">",
"      Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/8\">",
"      Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol Oncol 2009; 115:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/9\">",
"      Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/10\">",
"      Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24:4699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/11\">",
"      Markman M, Moon J, Wilczynski S, et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 2010; 116:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/12\">",
"      Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28:3323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/13\">",
"      Joly F, Ray-Coquard I, Fabbro M, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/14\">",
"      Bozas G, Bamias A, Koutsoukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 2007; 104:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/15\">",
"      Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012; 107:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/16\">",
"      Joly F, Petit T, Pautier P, et al. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. Gynecol Oncol 2009; 115:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/17\">",
"      Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/18\">",
"      Xenidis N, Neanidis K, Amarantidis K, et al. Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer. Cancer Chemother Pharmacol 2011; 67:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/19\">",
"      Herrero AB, Mart&iacute;n-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006; 66:8155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/20\">",
"      Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     Aghajanian C, Blank S, Goff B, et al. Results from a 2nd interim OS analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Presented at the 2012 Society of Gynecologic Oncologists Annual Meeting, Abstr 2289, Austin, TX.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/22\">",
"      Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/23\">",
"      Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/24\">",
"      Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/25\">",
"      Morris R, Alvarez RD, Andrews S, et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol 2008; 109:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/26\">",
"      Mitchell SK, Carson LF, Judson P, Downs LS Jr. Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. Int J Gynecol Cancer 2005; 15:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/27\">",
"      Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001; 83:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/28\">",
"      Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/29\">",
"      Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009; 27:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/30\">",
"      Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/31\">",
"      Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/32\">",
"      Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 97:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/33\">",
"      Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22:3120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/34\">",
"      Hurteau JA, Brady MF, Darcy KM, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol 2010; 119:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/35\">",
"      Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007; 13:3617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/36\">",
"      Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877.",
"     </a>",
"    </li>",
"    <li>",
"     Sales E, Penson RT, Sullivan LA, et al. A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. J Clin Oncol 30, 2012 (suppl; abstr 5029).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/38\">",
"      Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/39\">",
"      Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/40\">",
"      Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/41\">",
"      Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/42\">",
"      Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/43\">",
"      Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/44\">",
"      Armstrong DK. Exploratory Phase 2 Efficacy Study of MORAb-003, a Monoclonal Antibody against Folate Receptor Alpha, in Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse. Joint ECCO 15 - 34th ESMO Multidisciplinary Congress 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/45\">",
"      Penson RT, Whalen C, Lasonde B, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2011; 29: Abstract 5004.",
"     </a>",
"    </li>",
"    <li>",
"     Oza Am, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. J Clin Oncol 30, 2012 (suppl; abstr 5001)",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37209/abstract/47\">",
"      Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol 2012; 19:4052.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16755 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37209=[""].join("\n");
var outline_f36_21_37209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1846265641\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1846264236\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1846264320\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4501538\">",
"      Selection of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1846264327\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1846264342\">",
"      - Is there a role for bevacizumab?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1224704057\">",
"      Single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H468387732\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H468386265\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23567221\">",
"      Recurrence based on CA-125 only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23567167\">",
"      Genome wide tumor analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111338810\">",
"      In vitro chemosensitivity and resistance assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1224704477\">",
"      Retreatment with carboplatin and risk of hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4501699\">",
"      Is there a role for maintenance?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H468387753\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16216188\">",
"      Heated intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1846265641\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/57/7070\" title=\"table 1\">",
"      Paclitaxel and carboplatin chemotherapy for EOC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28070?source=related_link\">",
"      Surgery for recurrent epithelial ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=related_link\">",
"      The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37210="Creating an arteriovenous fistula for hemodialysis";
var content_f36_21_37210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Creating an arteriovenous fistula for hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Gerald A Beathard, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Eric K Peden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/21/37210/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/21/37210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three principal forms of chronic vascular access for hemodialysis are native arteriovenous fistulas (native AVFs), arteriovenous shunts using graft material (AV graft), and tunnelled double-lumen catheters. Of these, the native AVF is preferred for long-term hemodialysis vascular access since it has the best long-term primary patency rate, requires the fewest interventions of any type of access, and most importantly, AVFs are associated with the lowest incidence of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The National Kidney Foundation Kidney Disease Quality Outcomes Initiative (NKF-KDOQI) clinical practice guidelines suggest a goal prevalence rate for native AVF of 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/6\">",
"     6",
"    </a>",
"    ]. To achieve these goals, disparities in the successful creation of native AVF need to be overcome. In most studies, fewer AV fistulas are reported in female than in male hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/7-11\">",
"     7-11",
"    </a>",
"    ], and in African-American compared with non-African-American hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. The explanation for gender and racial differences is not totally clear; however, it has been shown that there is a greater risk of primary failure in both women and African-Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The creation of native AVFs for hemodialysis patients is reviewed here. An overview of the different types of chronic hemodialysis access is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CHARACTERISTICS AND BENEFITS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native arteriovenous fistulas (AVFs) are preferred over other forms of chronic hemodialysis access and we recommend placement of an AVF rather than an AV graft or tunnelled double-lumen central catheter, whenever possible. However, the temptation to create an arteriovenous fistula to satisfy the fistula-first initiative in patients with inadequate vessels should be resisted. Overly aggressive attempts to increase AVF prevalence in patients with suboptimal anatomy leads to reduced maturation rates, and a longer duration of dialysis catheter use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Patients with inadequate vessels'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefits of AVFs over other forms of chronic access are summarized below and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=see_link&amp;anchor=H7#H7\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\", section on 'Comparison of fistulas and grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AVFs are associated with decreased morbidity and mortality among hemodialysis patients compared with AV grafts and central venous catheters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AVFs have the superior primary patency rates, the lowest rates of thrombosis, and require the fewest secondary interventions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/4,19-21\">",
"       4,19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AVFs generally provide longer hemodialysis access survival rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/2,4,19,21-24\">",
"       2,4,19,21-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The total number of interventions during the life of the access is considerably lower for AVFs compared with AV grafts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/4,19,23\">",
"       4,19,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AVFs have lower rates of infection than AV grafts and significantly lower infection rates compared with percutaneous catheters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/5,25\">",
"       5,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with AVFs have lower hospitalization rates than patients with AV grafts or catheters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cost of implantation and maintenance of AVFs is the lowest of the three types of access [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/4,6,8\">",
"       4,6,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Features",
"    </span>",
"    &nbsp;&mdash;&nbsp;All arteriovenous fistulas (AVFs) possess similar characteristics. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AVFs can be created with minimal patient morbidity. The surgical procedure is relatively straightforward and is generally quickly accomplished, with the exception of the brachial-basilic fistula and other transposed AVFs. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types of native AVF'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is an increase in venous blood flow with time, which has the potential for causing cardiac overload in susceptible patients (see",
"      <a class=\"local\" href=\"#H107110138\">",
"       'Cardiac disease'",
"      </a>",
"      below). The diameter and flow within the associated artery also increases with an abrupt initial increase at the time of fistula creation, and a continued gradual increase thereafter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. These alterations in flow may lead to distal extremity ischemia. Steal is more likely in patients undergoing brachial-based arteriovenous fistulas than in those with radial artery-based fistulas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link&amp;anchor=H12722337#H12722337\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\", section on 'Extremity ischemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The AVF increases in diameter with time, which may cause cosmetic concern on the part of the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TYPES OF NATIVE AVF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are arteriovenous fistulas (AVFs) that are more commonly created, a fistula can be fashioned anywhere a vein of sufficient diameter is located or can be moved into position near and anastomosed to an artery of adequate size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368959032\">",
"    <span class=\"h2\">",
"     Types by method of creation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fistula types are classified as simple direct, vein transposition, or vein translocation based upon how they are created. Each is discussed in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Simple direct fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple direct fistula is a straightforward fistula to create since the vein and the artery are used in their normal positions. The distal end of the vein is dissected free and sutured to an adjacent artery. Examples are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radial artery-to-cephalic vein (forearm)",
"     </li>",
"     <li>",
"      Radial artery-to&ndash;basilic vein (forearm, in some cases, generally requires transposition)",
"     </li>",
"     <li>",
"      Radial artery-to-median antecubital vein (forearm)",
"     </li>",
"     <li>",
"      Radial artery&ndash;to-median antebrachial (forearm)",
"     </li>",
"     <li>",
"      Brachial artery-to-cephalic vein (upper arm)",
"     </li>",
"     <li>",
"      Tibial artery-to&ndash;saphenous vein (lower extremity)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Vein transposition fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a vein transposition fistula, the vein is moved or transposed to a position that is better suited for the construction of a fistula. Although the downstream or proximal end of the vein is left intact, the distal portion is transposed to a position that will facilitate ease of cannulation when the fistula is used for hemodialysis. This requires the creation of a tunnel or pocket to serve as a bed for the newly positioned vein. This is occasionally performed in a two-stage operation. Examples are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radial-cephalic transposition (forearm, in obese patient)",
"     </li>",
"     <li>",
"      Radial-basilic transposition (forearm, in most patients)",
"     </li>",
"     <li>",
"      Brachial-basilic transposition (upper arm)",
"     </li>",
"     <li>",
"      Brachio-brachial transposition",
"     </li>",
"     <li>",
"      Brachial-cephalic transposition (upper arm, obese patient)",
"     </li>",
"     <li>",
"      Femoral-saphenous transposition (thigh)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vein translocation fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a vein translocation fistula, a vein is removed from its normal anatomical location to another, and thus, requires the creation of a veno-venous anastomosis and veno-arterial anastomosis. The construction of a vein translocation fistula is similar to the placement of an AV graft. The only difference is that the patient's vein is used instead of prosthetic material. The procedure similarly requires the creation of a subcutaneous tunnel to position the vein into its new location. This type of AVF is infrequently needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Types by anatomic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of AVF should be referred to by the specific artery and vein that are involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/7\">",
"     7",
"    </a>",
"    ]. The vascular anatomy of the upper extremity is illustrated in the figures (",
"    <a class=\"graphic graphic_figure graphicRef55596 graphicRef61941 \" href=\"mobipreview.htm?5/55/6008\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although a variety of different anatomic types of AVF can be created, most AVFs fall within three basic types:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radial-cephalic, which is the radial artery and the cephalic vein",
"     </li>",
"     <li>",
"      Brachial-cephalic, which is the brachial artery and the cephalic vein",
"     </li>",
"     <li>",
"      Brachial-basilic, which is the brachial artery and the basilic vein",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radial-cephalic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the three basic types of AVF, the radial-cephalic fistula is the most straightforward to create. The classic Cimino fistula is created using a side-to-side anastomosis between the artery and vein but can be complicated by venous hypertension in the hand as the fistula develops. To avoid this problem, most radial-cephalic fistulas are created by transecting the vein and creating an end-to-side anastomosis. Although the radial-cephalic AVF has a lower blood flow rate than is possible with more proximal AVFs, its use as the first access preserves the proximal arm vessels for later access attempts, as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Brachial-cephalic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brachial-cephalic fistula is created by anastomosing the upper arm cephalic vein to the brachial artery in the antecubital fossa or just above the elbow (transposition). It is more easily created than a brachial-basilic fistula because it requires less dissection, unless a long segment of cephalic vein needs to be mobilized to transpose the vein closer to the skin. Because of the lateral and relatively superficial location of the cephalic vein, the brachial-cephalic fistula is easy to cannulate. It also provides a long length of straight vein from which to select cannulation sites. This more proximal access has the potential for a higher blood flow than the radial-cephalic fistula but also has a slightly higher incidence of vascular steal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link&amp;anchor=H12722337#H12722337\">",
"     \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\", section on 'Extremity ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Brachial-basilic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brachial-basilic fistula (basilic vein transposition) requires more experience for successful creation. The basilic vein lies on the inner surface of the forearm in the median bicipital sulcus. It continues proximally to the middle third of the sulcus at which point it pierces the brachial fascia to run in a deeper plane. Thus, the vein must be elevated and transposed to make it usable as a hemodialysis access. The basilic vein is dissected free from its bed by ligating and dividing all tributaries to the point where it joins the brachial vein to form the axillary vein in the upper arm. The basilic vein is then elevated to make it superficial and transposed to move it from its medial position to a more lateral location that is accessible for dialysis. Brachial-basilic AVF is associated with more morbidity related to its creation. However, because the basilic vein is more deeply positioned and therefore less accessible for venipuncture under normal circumstances, it tends to be better preserved and less involved with postphlebitic changes compared with the cephalic vein.",
"   </p>",
"   <p>",
"    The basilic vein is shorter than the cephalic vein, especially if its confluence with the brachial vein is low in the upper arm. Under this circumstance, there is less potential cannulation length with which to work. This shorter length, along with its more medial location, makes the brachial-basilic fistula somewhat more difficult to cannulate.",
"   </p>",
"   <p>",
"    Steal syndrome tends to be more common for brachial artery-based fistulas. This may in part be related to its larger size. In addition, the basilic vein access tends to be used primarily in patients who have had multiple prior failed access procedures. These patients, as a group, tend to have a higher incidence of arteriosclerotic arterial disease, making them more susceptible to steal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link&amp;anchor=H12722337#H12722337\">",
"     \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\", section on 'Extremity ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ORDER OF PREFERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to NKF-KDOQI Clinical Practice Guidelines, the order of preference for the creation of AVF is radial-cephalic, brachial-cephalic, and then brachial-basilic transposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/29\">",
"     29",
"    </a>",
"    ]. We agree with this ranking. The 2008 Society for Vascular Surgery guidelines also state that a radial-cephalic access is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The order of preference is based upon the following rationale, which emphasizes ease of construction and minimization of patient morbidity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach of starting distally allows the preservation of more proximal veins for later use.",
"     </li>",
"     <li>",
"      The ranking order takes into account the ease of access creation and the degree of patient morbidity involved. Cephalic-based fistulas are more easily created, whether in the forearm or the upper arm.",
"     </li>",
"     <li>",
"      Vascular steal is more common in patients with more proximal (brachial artery-based) compared with distal (radial artery-based) fistulas as noted in observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=see_link&amp;anchor=H12722337#H12722337\">",
"       \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\", section on 'Extremity ischemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In making this order of preference recommendation, the middle arm (proximal forearm) has been ignored, which is unfortunate. Reports of the use of the proximal radial artery as the inflow vessel in the creation of a &ldquo;middle arm&rdquo; fistula have shown excellent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The proximal radial artery is positioned anteriorly and can be mobilized easily to create a tension-free anastomosis with the median antebrachial vein. This proximal radial-median antebrachial fistula is generally bidirectional, allowing for cannulation in both the forearm and upper arm. It also has less risk of steal syndrome compared with fistulas created using the brachial artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/33\">",
"     33",
"    </a>",
"    ], and provides superior results in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/36\">",
"     36",
"    </a>",
"    ], elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/37\">",
"     37",
"    </a>",
"    ], and patients with a difficult access arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/36\">",
"     36",
"    </a>",
"    ]. The suitability of the median-antebrachial vein may be contributed to in part by the fact that it is not commonly accessed by the venipuncturist. The reported results with this fistula make it apparent that it should be included on the list of preferred fistula types.",
"   </p>",
"   <p>",
"    If it is not possible to create one of the basic types of AVF, then all reasonable attempts at creating a transposed fistula should be exhausted before consideration is given to the insertion of an AV graft. In the event that a graft is placed, it should be done with the plan that it will be used for the dual purposes of providing dialysis access during its problem-free life expectancy (however long that may be) and for the development of the upper arm veins for the later creation of a secondary fistula once the use of the AV graft becomes problematic.",
"   </p>",
"   <p>",
"    The constant goal should be to increase AVF prevalence since, as summarized above, AVFs provide patients with end-stage renal disease with a dialysis access with the lowest morbidity and mortality and best long-term patency. The basic principle is that a well-functioning fistula is always better than the alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/17,19,22,23,38,39\">",
"     17,19,22,23,38,39",
"    </a>",
"    ], although there are some reports that do not agree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In planning the creation of an AVF, attention should be directed to the nondominant arm first. While the patient is on dialysis, having the dominant hand free allows the patient to engage in desired activities more easily. However, if the nondominant arm is not suitable for AVF creation, the dominant arm should be evaluated. Although not as convenient to the patient, a good AVF in any location is preferable to an AV graft.",
"   </p>",
"   <p>",
"    The importance of vascular mapping in attaining the goal of an optimum vascular access cannot be overstated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/42\">",
"     42",
"    </a>",
"    ]. It is critical that all of the various sites that could be used for AVF creation on the basis of normal and variant anatomy are identified. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Venous evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Early imaging and secondary surgical procedures should be electively performed to rescue AVFs that fail to adequately mature. (See",
"    <a class=\"local\" href=\"#H45\">",
"     'Follow-up to assess maturation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     AVF REQUIREMENTS FOR USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several characteristics must be present for an AVF to be usable. These include the following, which are discussed in more detail below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AVF must be accessible with the patient in a sitting position",
"     </li>",
"     <li>",
"      In the forearm, the AVF should be on the volar surface",
"     </li>",
"     <li>",
"      In the upper arm, the AVF should be on the anterior or lateral surface",
"     </li>",
"     <li>",
"      The AVF must be able to be reliably cannulated repeatedly",
"     </li>",
"     <li>",
"      The AVF should be within 1 cm of the skin surface",
"     </li>",
"     <li>",
"      A relatively straight segment needs to be available for cannulation",
"     </li>",
"     <li>",
"      Blood flow must be adequate to support the dialysis prescription",
"     </li>",
"     <li>",
"      The fistula must be adequately mature",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28054066\">",
"    <span class=\"h2\">",
"     Anatomic accessibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AVF must be created in an anatomical location that is accessible with the patient in a sitting position. A fistula that is located on the dorsal surface of the forearm or medial upper arm is not easily used. The ideal locations are on the volar surface of the forearm, the lateral surface of the upper arm or, in the case of a brachial-basilic fistula, the anterior surface of the upper arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Superficial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fistula must be within 1 cm of the skin surface for it to be reliably cannulated. A fistula that is large but deep is a problem since it is difficult to cannulate. A depth of 0.5 cm is optimum.",
"   </p>",
"   <p>",
"    In obese patients, an excellent AVF may be totally unusable because of its depth. This frequently is the case with upper arm AVFs in these patients, but it can also be a problem for forearm access. If an AVF can&rsquo;t be reliably palpated, it is too deep to be reached by the dialysis needle. In these patients, the vein can be dissected free by dividing and ligating the tributary veins and brought up to a more superficial position (superficialization) or, alternatively, lipectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/43\">",
"     43",
"    </a>",
"    ] or liposuction can be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H100368056\">",
"     'Obesity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Straight segment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AVF must have a relatively straight segment available for cannulation. At a minimum, the length should be at least several centimeters (DOQI guidelines suggest 6 cm) since the dialysis needle must be threaded into the vein to be stably positioned. Threading a needle into a tortuous fistula can lead to puncture of the opposite vein wall, and bleeding.",
"   </p>",
"   <p>",
"    Unfortunately, a straight segment is not always present. In these cases, transposition may be needed to provide a straight segment of vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28054078\">",
"    <span class=\"h2\">",
"     Blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;To be used as a dialysis access, an AVF must be able to sustain the blood flow rate that is demanded by the dialysis prescription. Adequate blood flow generally means a minimum flow rate in the range of 600 to 700",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    However, since an AVF can stay patent with a relatively low blood flow, the flow in the fistula does not have to be as great as that in grafts. As an example, in a study of radial-cephalic AVF maturation in 43 patients, fistula function was evaluated postoperatively by clinical examination and AVF blood flow measured noninvasively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/26\">",
"     26",
"    </a>",
"    ]. The blood flow in AVFs providing adequate dialysis was significantly higher compared with AVFs not providing adequate dialysis at 1 (754 versus 440",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    7 (799 versus 524",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and 42 days (946 versus 532",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Maturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AVF must be adequately mature to allow repeated cannulation. The native vein has a rather thin wall and is relatively fragile. The high pressure and flow artificially introduced when a fistula is created causes the involved vein to undergo a series of changes characterized by dilation and thickening of the wall.",
"   </p>",
"   <p>",
"    This process, referred to as maturation, eventually renders the fistula usable as a vascular access. Data collected by the Dialysis Outcomes and Practice Patterns Study (DOPPS) found no significant difference in AVF survival whether the AVF was first cannulated within 15 to 28 days or had a longer maturation period of 43 to 84 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/45\">",
"     45",
"    </a>",
"    ]. It was only if the AVF was first cannulated within 14 days of creation that a significant detrimental effect on the AVF was seen. Cannulation within 14 days of creation was associated with a 2.1-fold increased risk of subsequent fistula failure compared with fistulae cannulated at more than 14 days. Thus, we recommend waiting until at least 14 days after creation to cannulate an AVF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28054089\">",
"    <span class=\"h1\">",
"     TIMING OF AVF CREATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to realize that it takes time to arrive at a successful AVF. There are a number of events that must take place, including referral to surgery, surgical evaluation, scheduling for surgery, a period of maturation, and the possibility of a need for a salvage procedure to achieve usability which may be followed by another waiting period before it is finally declared suitable for use. Each of these events takes time. This sequence has been referred to as the &ldquo;fistula hurdles.&rdquo; During this sequence, the patient unfortunately falls into one of two categories: (1) continuing dialysis with a catheter or (2) the risk of having to start dialysis with a catheter. Either of these is undesirable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      According to one report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/46\">",
"       46",
"      </a>",
"      ], within a cohort of 78 patients who started dialysis with a tunneled catheter, it was observed that the likelihood of using a permanent access was 53 percent by six months and only 80 percent by one year. In patients with both a catheter and an immature access, 50 percent were using their permanent access at three months, and 80 percent at six months. Of patients using a catheter with access surgery pending, 45 percent had access surgery performed within three months, and only 70 percent at six months.",
"     </li>",
"     <li>",
"      It is well documented that patients who see a nephrologist prior to the need for dialysis have a better chance of starting dialysis with an AVF as a permanent access [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. However, even when patients are referred to a nephrologist prior to their need, they frequently incur a delay in having a permanent arteriovenous access placed and require catheter-based dialysis.",
"     </li>",
"     <li>",
"      In one study, it was shown that patients referred within one month of initiating hemodialysis therapy used a dialysis catheter for a median of 202 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/49\">",
"       49",
"      </a>",
"      ]. For patients referred within one to four months, it was 64 days; within 4 to 12 months, the time was 67 days; and with referral greater than 12 months before initiating hemodialysis therapy, catheter use was still for a median of 19 days.",
"     </li>",
"     <li>",
"      In another study of 157 patients initiating dialysis therapy, a total of 73.2 percent had predialysis follow-up by a nephrologist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/50\">",
"       50",
"      </a>",
"      ]. Of these, only 46.5 percent had predialysis vascular access surgery and only 35 percent initiated their first dialysis session with a permanent access.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Access planning is a complex issue with a number of problems that must be addressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/51\">",
"     51",
"    </a>",
"    ]. It is very clear that there is a need for an improved algorithm relating declining renal function and timing the referral for access placement. Creating the AVF well before it is required for dialysis allows adequate maturation to take place prior to use and avoids the need for a dialysis catheter. Since there is no disadvantage to creating an AVF too early (not true for grafts), the patient should be sent to the surgeon well before the time of anticipated need. The question remains, however, as to when planning should begin.",
"   </p>",
"   <p>",
"    Fistula creation at least four months before starting chronic hemodialysis has been shown to be associated with the lowest risk of sepsis and death from the use of hemodialysis catheters. In this retrospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fistulas or grafts created at least four months before starting hemodialysis were defined as Early creations (n = 1240)",
"     </li>",
"     <li>",
"      Accesses created between four months and one month before starting hemodialysis were defined as Just Prior creations (n = 997)",
"     </li>",
"     <li>",
"      Accesses created within one month of starting dialysis or after were defined as Late creations (n = 3687).",
"     </li>",
"     <li>",
"      Hemodialysis catheter use was defined as insertion, removal, or manipulation of a catheter before the occurrence of sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eighty percent of accesses were AVFs. Early access creation was associated with a decreased risk of sepsis compared with late access creation, with catheter use increasing the risk of sepsis by 1.41. Early access creation was also associated with lower mortality. Catheter use and sepsis independently increased mortality.",
"   </p>",
"   <p>",
"    We agree with the NKF-KDOQI Clinical Practice Guidelines that, in order to give the patient a better chance of having a functional permanent access at the initiation of dialysis therapy, a fistula should be placed early before the anticipated start of hemodialysis treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/53\">",
"     53",
"    </a>",
"    ]. Time is required for access evaluation post-surgery and additional time for possible salvage procedures to ensure that a working fistula is available at initiation of dialysis therapy. However, the timing should be based upon objective criteria rather than an estimate. We propose the use of a simple algorithm, referred to as the &ldquo;30&ndash;20&ndash;10 rule,&rdquo; based upon estimated GFR to determine the time for access planning as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GFR 30 &ndash; Initiate education of the patient and family relating to ESRD management including the options of transplantation, dialysis alternatives, and dialysis access",
"     </li>",
"     <li>",
"      GFR 20 &ndash; Initiate access placement (arteriovenous, peritoneal) and initiate work-up for the transplant list",
"     </li>",
"     <li>",
"      GFR 10 &ndash; Initiate dialysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION PRIOR TO ACCESS PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adequate evaluation of the predialysis patient with chronic kidney disease enhances the opportunity to place a functioning AVF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;To determine the type of access most suitable for a patient, a general physical examination and a detailed medical history is first performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emphasis should be placed on aspects that might affect the placement of the vascular access with special attention given to an evaluation for the risk factors below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any physical evidence (scars) that the patient had a prior central venous catheter should be documented. In most, but not all instances, the patient will give a positive history [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient's chest, breast, and upper arms should be evaluated for the presence of swelling or collateral veins. In patients with normal venous pressure, central venous occlusion may not be associated with swelling; however, the presence of collateral veins should alert the examiner to the problem. The presence of scars, indicating prior neck or thoracic surgery or trauma, should also raise the possibility of a venous anomaly that might affect access creation.",
"     </li>",
"     <li>",
"      The presence of a cardiac implantable electronic device (CIED) such as a permanent cardiac pacemaker or other device should be noted. The wires associated with these devices are at high risk for causing central vein stenosis. Thus, it is important to avoid hemodialysis access ipsilateral to transvenous pacemakers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arterial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a fistula is created between the arterial and venous circulation, as in the creation of a dialysis AVF, the goal is to create an accessible vascular structure with sufficient blood flow that can be cannulated repeatedly to permit adequate dialysis. However, the anastomosis that is created is a low resistance circuit that redirects blood flow to the venous outflow instead of into the hand with the potential for distal ischemia.",
"   </p>",
"   <p>",
"    The presence of an optimally functioning dual circulation to the hand, as represented by the radial and ulnar arteries connected distally through the superficial and deep palmar arches, is an important safety mechanism against ischemia. When the radial artery is used for the AVF, the ulnar artery can adequately support the perfusion of the hand. Unfortunately, the palmar arch may also allow blood derived to be diverted to the radial-based fistula bypassing the hand. Although asymptomatic hemodynamic steal after AV access creation is very common, symptomatic steal occurs in a minority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/56\">",
"     56",
"    </a>",
"    ]. The goal of the arterial evaluation is to ensure adequate blood flow and an intact dual blood supply to the hand.",
"   </p>",
"   <p>",
"    The artery must also be capable of delivering blood flow at a rate adequate to support dialysis. Arterial calcification resulting in stenosis is relatively common in patients with end-stage renal disease, particularly those with diabetes or hypertension. Severe peripheral artery disease is common in patients with access-related hand ischemia (&gt;90 percent) and is an important marker for the risk of this problem following hemodialysis access surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/31,57\">",
"     31,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral artery disease can be diagnosed preoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/28\">",
"     28",
"    </a>",
"    ]. In a study of 72 patients undergoing brachial artery-based hemodialysis access, complete preoperative and postoperative arterial examinations were performed. Fourteen patients (19 percent) subsequently developed arterial steal symptoms and were attributed to proximal arterial stenoses in seven patients and distal disease in five; the cause was unknown in only two patients. We suggest evaluation of bilateral upper extremity blood pressures, pulse examination, Allen test, and arterial imaging if indicated, prior to access creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in blood pressure between the two arms should be should be reported and graded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/7\">",
"     7",
"    </a>",
"    ]. A difference of less than 10 mmHg should be considered normal. A difference of 10 to 20 mmHg is considered marginal and over 20 is definitely problematic. A difference of 20 mmHg or greater is suggestive of subclavian artery stenosis in the low pressure arm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H146789830#H146789830\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Upper extremity segmental pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Assessment of pulses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axillary, brachial, radial, and ulnar pulses should be examined in both upper extremities. The quality of these pulses should be documented as normal, diminished, or absent. A handheld Doppler device is useful for this purpose (",
"    <a class=\"graphic graphic_picture graphicRef56662 \" href=\"mobipreview.htm?40/6/41057\">",
"     picture 1",
"    </a>",
"    ). Ideally, all the pulses should be palpable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Allen test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The palmar arch, which should be patent, can be tested using the Allen test, or more accurately stated, the modified Allen test. Utilization of this test can detect patent ulnar and radial arteries supplying the palmar arch, and thus the digits. When performed with the aid of a pulse oximeter or vascular Doppler, this test has been found to be reliable in 95 to 100 percent of patients being evaluated for future hemodialysis access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Allen test has been criticized as being unreliable with considerable inter-operator variation in performance and interpretation. This is due to the fact that, as commonly performed, it is largely subjective, and there are pitfalls in inexperienced hands. The use of a pulse oximeter, to detect the pulse wave, or a vascular Doppler, to evaluate pulse augmentation, can increase the effectiveness of the Allen test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/62\">",
"     62",
"    </a>",
"    ]. There are no comparative studies that have examined the relative efficacy of pulse oximeter and vascular Doppler in this setting. Nevertheless, the use of either of these approaches moves the test from a subjective to an objective evaluation.",
"   </p>",
"   <p>",
"    We suggest using the pulse oximetry as an aid to the Allen test to evaluate hand collateral circulation. The pulse oximetry probe should be placed on the patient's index finger. Next, the ulnar and radial arteries should be compressed. The loss of the pulse oximeter waveform and oxygen saturation reading is an objective indication that compression is adequate. Subsequent return of a pulse and oxygen saturation reading following the release of the ulnar artery indicates a negative test, ie, adequate ulnar collateral circulation. The test can then be repeated with release of the radial to demonstrate adequacy of that circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Arterial imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to image the artery that will be used for the creation of the fistula. To avoid the risks and complications associated with arteriography, we recommend duplex ultrasonography.",
"   </p>",
"   <p>",
"    The routine use of ultrasonography prior to fistula creation is associated with a lower AVF failure rate. This was best demonstrated in a randomized trial of 218 patients with end-stage renal disease who were referred for access creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/64\">",
"     64",
"    </a>",
"    ]. All patients were assessed by physical exam and ultrasound; after randomization, the ultrasound report was provided to the surgeon for patients in the ultrasound but not control group. The ultrasound group had a lower rate of immediate failure, (4 versus 11 percent, respectively), and among failed fistulas, a lower rate of thrombosis (38 versus 67 percent respectively). The one-year assisted primary AVF survival, (defined as the patency and usability for dialysis from the time of access creation until thrombosis, including time gained by salvage procedures), was better in the ultrasound group compared with control (80 versus 65 percent, respectively), although the one-year overall survival (ie, patency and usability from the time of access creation to the date of the first access failure) was not different between groups (56 versus 65 percent respectively).",
"   </p>",
"   <p>",
"    When the vessel is examined, the presence of any calcification should be documented. If the artery has calcium deposits in its wall, it may be difficult to use. If it is heavily calcified, it will be extremely difficult to use.",
"   </p>",
"   <p>",
"    A preoperative arterial diameter less than 1.6 mm at the point of the anastomosis is associated with a high risk of failure for radial-cephalic fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. In one prospective study of 116 patients, patency rates after surgery in a group with internal diameters of greater than 1.6 mm was 93 percent versus only 32 percent in those with internal diameters of less than 1.6 mm. Others have suggested that a diameter of 2 mm or greater should be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/58,68\">",
"     58,68",
"    </a>",
"    ]. This 2 mm requirement has been widely adopted, but has not been validated. If the desired arterial size or character is not evident where the anastomosis was initially anticipated, the anastomosis can be created more proximally on the vessel. With this strategy, a successful fistula may still be possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It would seem logical that there should be some consideration given to the patient's stature and habitus in making a decision as to what is acceptable for access creation. This is especially true in children. Although most children on hemodialysis utilize a central venous catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], it has been suggested that success with pediatric vessels can be achieved using microsurgical techniques where success rates in the range of those reported for AVF creation in adults have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/72\">",
"     72",
"    </a>",
"    ]. In addition, the skill of the surgeon is extremely important, and in fact may be more predictive of successful dialysis access than other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H100368101\">",
"     'Risk factors for AVF failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100368021\">",
"    <span class=\"h3\">",
"     Arterial requirements for AVF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, the arterial requirements for an AVF are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unobstructed inflow to the AVF",
"     </li>",
"     <li>",
"      Patent palmar arch",
"     </li>",
"     <li>",
"      Luminal diameter 2.0 mm or greater at the site of the planned anastomosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is possible to successfully treat arterial lesions associated with fistulas that fail to develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/76\">",
"     76",
"    </a>",
"    ], any evidence of peripheral artery disease initially detected during the arterial evaluation should be cause for concern. Diminished blood flow is likely and places the distal extremity at risk for ischemia and inadequate blood flow during dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/77\">",
"     77",
"    </a>",
"    ]. However, a less than optimal artery can be used to create a working fistula. In one report, patients with mild arterial lesions accounting for failure of fistula development were treated by percutaneous angioplasty with good results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/76\">",
"     76",
"    </a>",
"    ]. But, if a lesion is not likely to be successfully treated, attention should be turned to the opposite arm.",
"   </p>",
"   <p>",
"    If the radial artery is not patent, then a radial artery-based fistula is obviously not possible. If the ulnar artery is dysfunctional, the risk for steal is high if the radial artery is used. In these cases, attention should similarly be turned to the opposite arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Venous evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the placement of an access, we also recommend evaluation of the venous circulation on all patients. Accurate knowledge of venous anatomy is extremely important for access creation. If there is a vascular problem that will interfere with the creation of an AVF, it is more likely to be venous than arterial.",
"   </p>",
"   <p>",
"    Routine preoperative venous evaluation prior to placement of hemodialysis access consists of vein mapping, which is simply identifying the veins and evaluating their size and patency and evaluation of the central veins in patients with a history or clinical signs suggestive of central venous stenosis.",
"   </p>",
"   <p>",
"    Vein mapping increases in the likelihood of successful AVF creation and improves the adequacy of forearm fistulas for dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/58,78-82\">",
"     58,78-82",
"    </a>",
"    ]. In one study, preoperative sonographic evaluation of the upper extremity arteries and veins was obtained routinely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/82\">",
"     82",
"    </a>",
"    ]. Compared with historic controls, the proportion of patients who were able to dialyze with a fistula was doubled (34 to 64 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/82\">",
"     82",
"    </a>",
"    ]. An improvement in the initial rate of AVF adequacy for forearm fistulas also increased significantly (34 to 54 percent), particularly among women and patients with diabetes.",
"   </p>",
"   <p>",
"    Three methods are available for evaluating the venous circulation and include physical examination, ultrasound, and venography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mapping the extremity superficial veins can be performed by simple physical examination in some patients. This is best done using a blood pressure cuff inflated to a pressure about 5 mmHg greater than the measured arterial diastolic pressure. The blood pressure cuff should be left in place for no more than five minutes at a time. Unfortunately, due to obesity and deep veins, few patients are successfully mapped by physical examination alone.",
"   </p>",
"   <p>",
"    Even when it appears that an adequate physical exam is possible, imaging provides more detailed and accurate information of the venous system. In one study, patients were randomly assigned to physical examination alone to plan and guide AVF creation, or vein mapping using ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/83\">",
"     83",
"    </a>",
"    ]. In first group, 25 percent of patients had fistulas that did not develop; all had problems that would have been apparent with ultrasound evaluation. In the group with ultrasound-guided vein mapping, 94 percent developed functioning fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107109543\">",
"    <span class=\"h3\">",
"     Vein mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vein mapping of the venous system can be accomplished using duplex ultrasonography and venography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h4\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detailed preoperative vein mapping using ultrasound is the optimal method for imaging the venous anatomy prior to access placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/58,67,83\">",
"     58,67,83",
"    </a>",
"    ]. Ultrasound has the advantage of easily measuring the depth and diameter of the veins. The venous system should be evaluated with and without a tourniquet in place to evaluate vein distensibility, which has been shown to correlate with the success of AVF creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/30,84,85\">",
"     30,84,85",
"    </a>",
"    ]. Another advantage of ultrasound is that it is noninvasive and does not require administration of intravenous contrast agents. However, radiocontrast-induced nephropathy has not been shown to be an issue, as described in the next section. A disadvantage of ultrasound is that the central veins are not completely imaged, although it is possible to indirectly evaluate their patency by assessing phasicity of blood flow with respiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h4\">",
"     Venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venography provides a complete assessment of peripheral venous patency and continuity with the central veins and is ideal for identifying and potentially treating central venous stenosis. Although vein diameter and depth can be determined with venography, this is not as easily accomplished compared with ultrasound, which is one reason that venography is not as widely used as ultrasound for the preoperative venous evaluation prior to AVF creation. Another reason is concern over the risk of damage to residual renal function.",
"   </p>",
"   <p>",
"    Nevertheless, venography is a technique that provides excellent information. In one study of 129 patients with end-stage renal disease who had preoperative venography, no complications occurred. The patients were mostly middle-aged with a 53 percent incidence of diabetes mellitus. An AVF was able to be placed in 95 percent of patients and there were no unsuccessful surgical explorations. Early AVF failure was seen in 8 percent.",
"   </p>",
"   <p>",
"    The main disadvantage of venography, though not uniformly a problem, lies in the need to initiate an intravenous access in the hand to do an optimal study. The magnitude of the challenge is easily appreciated by anyone who manages patients with chronic renal disease given the lack of intravenous access sites in these patients.",
"   </p>",
"   <p>",
"    Most patients that will have vascular mapping performed have some residual renal function. This is an important consideration that must be kept in mind when doing this procedure, and there are many nephrologists who express concern over the use of radiocontrast media for venography. However, much of the data on radiocontrast-induced nephropathy was obtained at a time when high osmolar, ionic radiocontrast medium was used and administered in large doses. Since then, large clinical studies and metaanalyses have found that iso-osmolar or low-osmolar contrast medium substantially reduces the risk of nephropathy in high-risk patients compared with the use of high-osmolar contrast medium. Iso-osmolar radiocontrast has also been shown to be less nephrotoxic than the low osmolarity products. Increased volume of radiocontrast has also been associated with worsening postprocedural kidney function. Thus, restricting radiocontrast volume to decrease the risk is also advocated. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have failed to confirm a significant risk with current intravenous contrast agents and doses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 25 consecutive patients (CKD stage 4 and 5) undergoing venography were advised not to fast for the procedure and were encouraged to take oral fluids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/87\">",
"       87",
"      </a>",
"      ]. Radiocontrast media-induced nephropathy was defined as a 20 percent decrease in the estimated glomerular filtration rate (GFR) from the baseline value at 48 hours after contrast administration. Weekly telephone calls were made for a total of four weeks to assess the need for dialysis. Venography was performed by interventional nephrology using 10 to 20 cc of low osmolarity contrast medium. At 48 hours, there were no differences between the preprocedure and postprocedure GFRs. During the four-week phone call follow-up, only one patient needed dialysis.",
"     </li>",
"     <li>",
"      In another study of 34 patients with stage 4 CKD, radiocontrast media was used in performing 65 percutaneous fistula salvage procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/88\">",
"       88",
"      </a>",
"      ]. The mean contrast volume was 7.8 mL per procedure. The incidence of acute renal failure (defined as a 25 percent increase in serum creatinine level) was 4 and 5 percent at 2 and 7 days, respectively. All values returned to baseline within 2 weeks, and no patient required acute dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should be approached with caution to minimize the risk of inducing damage to the patient's residual renal function. We therefore recommend that a nonionic iso-osmolar agent be used when venography is performed and that the dosage be minimized to the extent that is possible to obtain an adequate study. If not contraindicated, the patient should also have their fluids and salt intake liberalized the day before, the day of, and the day after the procedure. We do not feel that a more vigorous regimen is required.",
"   </p>",
"   <p>",
"    Among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In these patients, gadolinium-based imaging should be avoided. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h4\">",
"     Choice between ultrasound and venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there have been no studies to compare ultrasound and venography, each is capable of providing adequate information for fistula creation. Each technique has advantages and disadvantages and each has its advocates. Ultrasound is most commonly used for the initial evaluation of venous anatomy and venography performed selectively under circumstances in which venous outflow stenosis is suspected. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With ultrasound, vein depth and diameter are easily determined and it is possible to do dynamic studies. Arterial evaluation can be performed during the same examination to determine the size and character (calcification) of potential arterial sites.",
"     </li>",
"     <li>",
"      Venography gives a more complete view of the overall venous system than is possible with ultrasound. In addition, it is an excellent technique for detecting areas of venous stenosis and determining the extent of the venous stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107109520\">",
"    <span class=\"h3\">",
"     Venous requirements for AVF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous requirements for an AVF are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/58,68,89\">",
"     58,68,89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unobstructed outflow from the fistula",
"     </li>",
"     <li>",
"      Luminal diameter of the venous outflow of &ge;2.5 mm",
"     </li>",
"     <li>",
"      Straight segment for cannulation",
"     </li>",
"     <li>",
"      Vein depth &lt;1 cm from the skin surface",
"     </li>",
"     <li>",
"      Direct continuity of the outflow vein with central veins",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Patients with inadequate vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of vascular evaluation prior to dialysis access placement is to determine the adequacy of anatomy for the creation of an AVF. However, the patient in whom the vessels are inadequate must also be treated effectively. It is not possible to present an algorithm that is universally applicable; individualization is required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with severe peripheral artery disease, peritoneal dialysis may offer the best opportunity for treatment.",
"     </li>",
"     <li>",
"      The placement of an AV graft can be the best option in some cases. When needed, the AV graft should be performed with two purposes in mind. First, to provide a useable dialysis access, and second, to develop veins in the upper arm for a secondary fistula when the AV graft becomes problematic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/90,91\">",
"       90,91",
"      </a>",
"      ]. The presence of the AV graft leads to changes in the outflow veins that are identical to those seen with fistula maturation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some data suggest that is possible to enhance the size of the necessary veins with upper extremity exercise or compression therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. However, by the time the patient needs a hemodialysis access, it is too late for these methods to be of much value. However, these methods may be helpful in a patient in whom dialysis is a distant possibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100368101\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR AVF FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patient characteristics, comorbidities and even community factors increase the risk for AVF failure. It is important that one understand this and develop a strategy for dealing with them as necessary. It is also important to keep in mind that while most patients should be viewed as candidates for an AVF, some patients are best served by an alternative type of dialysis access. Risk factors include inadequate anatomy, obesity, advancing age, female gender, medical conditions such as heart failure, and diabetes mellitus. Each of these is reviewed in more detail below.",
"   </p>",
"   <p>",
"    Many patients have more than one risk factor. It would be of value to be able to make some type of prediction of their overall risk of failure before an AVF is attempted. One report that looked at this issue used four factors to define risk categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/14\">",
"     14",
"    </a>",
"    ]. These factors were age greater than 65, the presence of peripheral artery disease, the presence of coronary artery disease and the race of the patient. Each of these criteria were given weighted numerical values which, when added, defined four risk categories which were termed low, moderate, high, and very high. The defined categories predicted the risk of AVF failure to mature to be 24, 34, 50, and 69 percent, respectively.",
"   </p>",
"   <p>",
"    In addition to these factors, the experience of the surgeon available to create vascular access varies, and can affect the likelihood of AVF placement and success of an AVF creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/73,95,96\">",
"     73,95,96",
"    </a>",
"    ]. A retrospective study evaluated the characteristics predictive of fistula placement and success among 148 patients referred to two different high-volume vascular access surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/96\">",
"     96",
"    </a>",
"    ]. Significantly higher percentages of AVF placement were observed with the community surgeon versus academic center surgeon (98 versus 71 percent). The most significant factors underlying placement of a fistula were surgeon choice and no history of diabetes. Six-month and 12-month overall access survival was significantly higher with the community surgeon.",
"   </p>",
"   <p>",
"    We agree with the National Vascular Access Improvement Initiative",
"    <strong>",
"    </strong>",
"    referred to as",
"    <strong>",
"    </strong>",
"    &ldquo;Fistula First&rdquo; Change Concepts 3 and 4 that state that [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nephrologists should communicate standards and expectations to surgeons performing access, eg, KDOQI minimal standards for AVF placement, and training in current techniques for AVFs.",
"     </li>",
"     <li>",
"      Nephrologists refer to surgeons willing and able to meet the standards and expectations.",
"     </li>",
"     <li>",
"      Surgeons are continuously evaluated on frequency, quality, and patency of access placements.",
"     </li>",
"     <li>",
"      Surgeons utilize current techniques for AVF placement, including vein transposition.",
"     </li>",
"     <li>",
"      Surgeons ensure mapping is performed for any patient not clearly suitable for AVF based only on physical exam.",
"     </li>",
"     <li>",
"      Surgeons work with nephrologists to plan for and place secondary AVFs in suitable AV graft patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107109965\">",
"    <span class=\"h2\">",
"     Inadequate anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inadequate size or quality of vessels may not be candidates for an AVF, at least initially. This is discussed above. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Patients with inadequate vessels'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    In these cases, the creation of a synthetic graft access in the forearm may be the best option. As discussed above, the purpose is twofold. The AV graft will provide a useable dialysis access, and the veins in the upper arm may develop over time such that a secondary AVF may be possible to create when the graft becomes problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100368056\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is common in patients who present for dialysis and these patients may have a reduced mortality compared with nonobese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. In addition, obesity and diabetes mellitus are often comorbidities. The creation of a functioning AVF in obese patients can be problematic. The veins tend to be deep due to the adiposity of the extremity, particularly in the upper arm. An AVF must be located superficially enough to identify landmarks that will allow safe cannulation. If the AVF is located too deeply from the skin surface, a procedure to elevate the fistula can be performed, which has been reported to be very successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/99\">",
"     99",
"    </a>",
"    ]. Alternatively, lipectomy or liposuction has also been proposed as a means to minimize the depth of AVFs in obese arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/43,44,100,101\">",
"     43,44,100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective cohort analysis was performed using the United States Renal Data System Dialysis Morbidity and Mortality Wave II data set to evaluate the relationships between obesity and vascular access outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/102\">",
"     102",
"    </a>",
"    ]. Obesity was not associated with increased AVF revision rates or failure, and was only associated with poorer AVF maturity at highest BMI quartile (&ge;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    However, in another study comparing obese with nonobese patients, secondary patency was significantly lower in obese patients, although the likelihood of fistula placement and primary patency rates were the same [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/103\">",
"     103",
"    </a>",
"    ]. It has been suggested that the decreased secondary patency in these patients could be due to soft-tissue compression of the venous outflow of the upper extremity in the adducted position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It would appear that when presented with an obese patient, vein mapping becomes particularly important. There is no reason to avoid the creation of an AVF, but superficialization by some means should be anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100368063\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the success of vascular access creation is dependent upon age becomes increasingly important as the age of the dialysis population increases. The incidence of peripheral artery disease and other comorbidities increases, and these could potentially have an effect on AVF success rates. Some have reported inferior patency rates of distal arteriovenous AVFs in elderly patients, and others present contradictory results.",
"   </p>",
"   <p>",
"    A meta-analysis involving 13 studies was performed to assess whether older adults (age &gt;65; one study age &gt;50) have the same risk of forearm arteriovenous AVF failure as younger patients, and whether distal access has the same risk of failure as more proximal access in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/105\">",
"     105",
"    </a>",
"    ]. This study found a significantly higher rate of radial-cephalic arteriovenous AVF failure in older patients compared with younger adults at 12 and 24 months. This study also suggested that brachial-cephalic AVFs were better than radial-cephalic fistulas in older patients. In a population of 205 dialysis patients with a 40 percent primary fistula failure rate (85 cases), age was a risk factor for failure with a hazard ratio [HR] of 1.98 (95% CI 1.10-3.70). Gender and AVF location were also significant risk factors with HR 2.42 (95% CI 1.29-4.10) and HR 2.25 (95% CI 1.0-3.06), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a single institution study, the primary patency rates at one and two years for radial-cephalic AVFs were similar for the age groups studied, and were 46.0 and 27.1 percent for patients &lt;65, 47.0 and 36.0 percent for those 65 to 79 years, and 45.7 and 38.1 percent for those &ge;80 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/106\">",
"     106",
"    </a>",
"    ]. The primary patency rates for brachial-cephalic AVFs at one and two years were also similar across the age groups at 39.3 and 31 percent for those &lt;65 years; 53.3 and 37.5 percent for those 65 to 79, and 46.3 and 42.6 percent for those &ge;80. The authors emphasized the need for patient selection at any age, but stressed their opinion that even an age of over 80 should not prohibit consideration for a radial-cephalic AVF. This seems to be the message as it relates to age. Patient selection is important; perhaps the major issue related to age is the increase in comorbidity that accrues with advancing years.",
"   </p>",
"   <p>",
"    Another important point that must be taken into consideration with the elderly patient relates to the length of time required to obtain a functioning AVF. The patient may die before the AVF is ready to use. One report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/107\">",
"     107",
"    </a>",
"    ] found that in a cohort of 48 patients &gt;70 years of age, 50 percent died within an 18 month period after having a fistula placed; only 8 of these patients were ever able to use their AVF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28054142\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon CMS data, there is a significant difference between fistula utilization in males and females. Although not supported by all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/108,109\">",
"     108,109",
"    </a>",
"    ], most single center reports that have looked at this issue have supported this view [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/8,12,110\">",
"     8,12,110",
"    </a>",
"    ]. The Dialysis Outcomes and Practice Patterns Study (DOPPS) suggests that this trend is global [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/111\">",
"     111",
"    </a>",
"    ]. One report indicated that gender was a significant risk factor with a hazard ratio of 2.42 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/13\">",
"     13",
"    </a>",
"    ]. This report also found that females younger than 65 had outcomes that were no better than males over 65 years of age.",
"   </p>",
"   <p>",
"    The reasons for this gender difference are not clear. It has been suggested that the relatively small vessels in the female make the creation a successful AVF more difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/112\">",
"     112",
"    </a>",
"    ]. However, studies have not been able to find evidence to support this theory. In a study of 230 newly placed fistulas, it was suggested that fistula development was inadequate and was apparent for both upper arm and forearm fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/8\">",
"     8",
"    </a>",
"    ]. A salvage procedure was significantly more likely in women than in men (42 versus 23 percent). This contention was supported by two other studies, in which female gender was an independent predictor of the fistula failing to mature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/13,110\">",
"     13,110",
"    </a>",
"    ]. The likelihood of fistula maturation after an intervention was similar among women and men (50 versus 37 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107110138\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular problems are common in patients with end-stage renal disease and cardiovascular mortality is 10 to 20 times higher in these patients compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The creation of an AVF has a significant cardiac effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. In a study of 16 patients with chronic renal failure who underwent AV fistula creation, serial changes in cardiac function were obtained immediately after the AV fistula operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/4\">",
"     4",
"    </a>",
"    ]. Significant elevations in cardiac output (15 percent) and left ventricular end-diastolic diameter (4 percent) were noted. Pulmonary hypertension can also be apparent immediately after the creation of an arteriovenous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/114,116\">",
"     114,116",
"    </a>",
"    ]. Affected patients have significantly higher cardiac output.",
"   </p>",
"   <p>",
"    On the other hand, some reports have noted an improvement in cardiovascular function with the creation of an arteriovenous dialysis access. At two weeks following creation of a new AVF, one study of 30 patients found decreased total peripheral resistance, a tendency for increased stroke volume, and increased heart rate and cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/117\">",
"     117",
"    </a>",
"    ]. Systolic and diastolic blood pressures were reduced, and left ventricular ejection fraction increased. All the observed changes were largely maintained after three months. No change in volume status or body composition was observed.",
"   </p>",
"   <p>",
"    For patients with relatively normal cardiac function, the creation of an AVF should not be expected to have adverse effects. However, in patients with significant cardiac disease, caution is maintained. A high-flow AVF (2,000",
"    <span class=\"nowrap\">",
"     cc/min",
"    </span>",
"    or more) should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/118\">",
"     118",
"    </a>",
"    ]. In cases with heart failure not controlled with fluid management, an AVF (or AV graft) may not be a good choice, and an access that has already been placed may need to be ligated. In addition, these patients also have a shortened life expectancy which affects the choice of dialysis route. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H791616603#H791616603\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Long-term catheters versus arteriovenous access'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107110166\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with diabetes is more likely to have cardiovascular disease compared with patients without diabetes. Patients with diabetes commonly display medial calcification of the peripheral arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/119\">",
"     119",
"    </a>",
"    ]. When hemodynamically significant, these lesions may hinder the maturation of a distal (wrist) AVF by preventing the compensatory hypertrophy of the feeding artery and the subsequent increase in the arterial flow. However, medial calcification is rare in the brachial artery. Thus, some authors express little enthusiasm for the creation of an AVF at the wrist in patients with diabetes. The construction of proximal forearm AVF as an initial approach has been suggested as an alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/120-123\">",
"     120-123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other investigators have reported that diabetes was not significantly associated with primary failures of radiocephalic AVF and that diabetics are as good candidates for distal AVF placement as patients without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/11,123-125\">",
"     11,123-125",
"    </a>",
"    ]. Unfortunately, these studies do not provide adequate information relating to patient selection. By carefully planning the location for the AVF, equal results appear to be possible in diabetic and nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/121\">",
"     121",
"    </a>",
"    ]. It has been suggested that a preoperative plain radiograph of the hand and forearm be obtained as part of the evaluation of the diabetic patient to look for vascular calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/119\">",
"     119",
"    </a>",
"    ]. If calcification is absent, then the construction of a distal AVF is feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107110386\">",
"    <span class=\"h2\">",
"     Approach in high-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the mission statement of the National Vascular Access Improvement Initiative",
"    <strong>",
"    </strong>",
"    referred to as",
"    <strong>",
"    </strong>",
"    &ldquo;Fistula First,&rdquo; that every patient should receive the optimal vascular access tailored to their needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/126\">",
"     126",
"    </a>",
"    ]. In most, but not all cases, this will be an AVF. However, in patients with a limited life-expectancy, who are receiving palliative dialysis, an AVF is not the best option due to the time (fistula hurdles) required until usability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/127\">",
"     127",
"    </a>",
"    ]. These patients are better served with a synthetic graft, or perhaps a catheter. How does one proceed in planning a vascular access, particularly in patients with adverse issues such as an older age, obesity, diabetes or female gender?",
"   </p>",
"   <p>",
"    For most patients, including difficult cases, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary goal of hemodialysis vascular access should always be to create an AVF because of the lower complication rate associated with them compared with AV grafts or hemodialysis catheters.",
"     </li>",
"     <li>",
"      The available data suggests that the presence of risk factors does",
"      <strong>",
"       not",
"      </strong>",
"      prevent the placement of an AVF for a particular individual. Studies reporting risk factors are important, but represent population statistics.",
"     </li>",
"     <li>",
"      The patient's unique situation must temper any decision related to vascular access. The goal is to provide optimal hemodialysis access for an individual patient; an assessment of risk factors for AVF failure and a thorough and well-performed evaluation of the arteries and veins are mandatory.",
"     </li>",
"     <li>",
"      For some patients, the best access for the patient may be an AV graft or even a tunneled catheter. However, one can arrive at this conclusion only after all alternatives for AVF placement have been considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     FOLLOW-UP TO ASSESS MATURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a fistula is created, it must develop to the point that it is usable. This principally means that the AVF must provide adequate blood flow to support the hemodialysis prescription and must support repeated cannulations. Prospective studies suggest that an AVF that will become adequate for dialysis is apparent relatively early in the postoperative period. Maturation can be judged with 80 percent accuracy by physical examination, and the major causes of failure to mature can also be diagnosed by physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/78\">",
"     78",
"    </a>",
"    ]. Thus, we recommend evaluation in the clinic four to six weeks after the creation of a new AVF. If the AVF does not appear to be developing adequately, it should be studied by performing a fistulogram. In addition, fistulas that fail to develop have a high incidence of correctable problems, and once these problems are addressed a high success rate can be expected. Correcting problems to facilitate AVF usability limits the need for tunneled catheters, which are associated with significant and serious complications. Interventions to manage correctable lesions in AVFs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18010?source=see_link\">",
"     \"Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11944?source=see_link\">",
"     \"Use of stents for venous stenosis associated with dialysis vascular access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination alone is a very good tool for assessing the status of a fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/128-132\">",
"     128-132",
"    </a>",
"    ]. The easiest, most economical, and perhaps the best way to evaluate the newly created fistula is to just do a physical examination using some very basic principles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/133\">",
"     133",
"    </a>",
"    ]. This approach is capable of determining the status of fistula development, but also detecting the site and nature of problems that may be impeding development. The specific elements of the physical examination of AVFs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41443?source=see_link\">",
"     \"Physical examination of the hemodialysis arteriovenous fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study was conducted of 142 consecutive patients who were referred for an arteriovenous fistula dysfunction to examine the accuracy of physical examination in the detection of stenotic lesions when compared with a fistulogram [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/131\">",
"       131",
"      </a>",
"      ]. There was strong agreement between physical examination and fistulography in the diagnosis of outflow and inflow stenosis. The sensitivity and specificity for the outflow and inflow stenosis were 92 and 86 percent and 85 and 71 percent, respectively. There was strong agreement beyond chance regarding the diagnosis of coexisting inflow-outflow lesions between physical examination and fistulography.",
"     </li>",
"     <li>",
"      In a cohort study of 100 patients, results in one dialysis unit with ultrasound flow measurements were compared with those of another unit evaluated clinically by physical examination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/132\">",
"       132",
"      </a>",
"      ]. A fistulogram was obtained in the ultrasound flow cohort if graft flow was less than 600",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      fistula flow was less than 450",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      or flow decreased more than 25 percent, and in the clinical cohort if there was a change in the access appearance, change in the bruit, or a sharp increase in venous resistance. The patients in the clinical cohort had similar primary patency (1199 days) as in the ultrasound flow cohort (1162 days), as well as the mean number of procedures. Angiographic procedures were also similar, with 56 percent of all patients having none.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased blood flow occurs very early after surgery. This is illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study, average arterial blood flow preoperatively was 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/134\">",
"       134",
"      </a>",
"      ]. Within 24 hours of surgery, the fistula blood flow was up to 472",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and by one week it had increased to 861",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      In another study, patients were divided into two groups based upon the internal diameter (&le;1.5 or &gt;1.5 mm internal diameter) of their feeding artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/135\">",
"       135",
"      </a>",
"      ]. Blood flow increased from a preoperative level of 46",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      to 184",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at one day, 202",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at one week, 274",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at three weeks, 488",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at eight weeks and 562",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      at 12 weeks in the group with the larger artery. In this group, the primary patency rate at 12 weeks was 83 percent compared with 36 percent.",
"     </li>",
"     <li>",
"      In a third study, no significant differences in fistula blood flow were found after the second, third or fourth month following creation and that vessel diameter changed very little [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data suggest that the combination of adequate fistula size and blood flow helps predict fistula maturation. In one retrospective study of 69 patients, fistula maturation was defined by the ability of an experienced dialysis nurse to successfully cannulate the fistula and the ability of the access to support a minimum dialysis blood flow of 350",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/27\">",
"     27",
"    </a>",
"    ]. A fistula diameter of greater than 0.4 cm was associated with a likelihood of 89 percent that it was adequate for dialysis, while a diameter of less than 0.4 cm resulted in only a 44 percent chance. The chances that the fistula would be adequate for dialysis were 84 percent if the flow was 500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or greater, but only 43 percent if it was less than this level. Combining the two variables increased the predictive value of the measurements. A minimum fistula diameter of 0.4 cm and a minimum flow volume of 500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    resulted in a 95 percent chance that the fistula would be adequate versus 33 percent if neither of the minimum criteria were met. Experienced dialysis nurses were also 80 percent accurate in predicting the ultimate utility of a fistula for dialysis.",
"   </p>",
"   <p>",
"    Whether a fistula is adequate for repeated cannulation is somewhat harder to judge than the presence of adequate blood flow. It principally involves characteristics that we refer to as maturation, which relates to the fistula's size and how it feels. There are other characteristics that are also important: arm position, configuration, and depth, discussed earlier. Although some of these can be measured, this evaluation also involves subjective elements that cannot be quantified.",
"   </p>",
"   <p>",
"    Maintenance of patency to permit adequate blood flow is necessary for adequate fistula development and eventual maturation. However, the ability to decrease the rate of thrombosis with antiplatelet therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) does not translate into an increased rate of suitable AVFs. This was best shown in a study in which 877 patients were randomly assigned to clopidogrel or placebo for six weeks, initiated within one day after fistula creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/21/37210/abstract/136\">",
"     136",
"    </a>",
"    ]. The study was stopped early because of efficacy, as fistula thrombosis was significantly lowered in those administered clopidogrel (53 versus 84, relative risk of 0.63, 95% CI 0.48-0.97). However, the incidence of failure to adequately mature for dialysis (defined as a blood pump rate of 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or more during 8 of 12 dialysis sessions) was similar in both groups (62 and 60 percent). The decision for early termination was also based upon additional analysis, suggesting that it was improbable that a benefit of clopidogrel on fistula maturation would be found if the trial had been completed. Thus, we do not recommend administration of clopidogrel as a means to increase the rate of fistula maturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All arteriovenous fistulas (AVF) possess similar characteristics. These generally include very low patient morbidity for most types of AVF related to the procedure, with the exception of transposition AVFs, an increase in size and blood flow with time, and lower rates of venous stenosis and infection than arteriovenous (AV) grafts. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General characteristics and benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based upon how they are created, AVFs can be classified into three different categories: simple direct, vein transposition, and vein translocation. AVFs should be referred to using anatomical designations that include the donor artery and outflow in their description, such as radial-cephalic, which is the radial artery and the cephalic vein; brachial-cephalic, which is the brachial artery and the cephalic vein; and brachial-basilic, which is the brachial artery and basilic vein. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Types by anatomic location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require a chronic hemodialysis vascular access, we recommend an AVF rather than an AV graft (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend arteriovenous access (AVF or AV graft) rather than a hemodialysis vascular catheter (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among the possible AVFs, we recommend a radial-cephalic fistula (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If a radial-cephalic fistula is not possible, we recommend a brachial-cephalic fistula (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If a radial-cephalic or brachial-cephalic fistula is not possible, we recommend a brachial-basilic fistula rather than other AVFs (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If one of these three basic fistula types is not reasonably feasible, a proximal radial-medial antebrachial fistula is an option that should be considered. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Types by anatomic location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To be usable, several characteristics must be present for an AVF. These include adequate blood flow, reliable repeated cannulation, accessibility in a sitting position, and adequate maturation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'AVF requirements for use'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We recommend that the AV fistula be created early enough to permit adequate maturation prior to the initiation of dialysis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although the optimal timing is unclear, we use the &ldquo;30-20-10 rule&rdquo;. (See",
"      <a class=\"local\" href=\"#H28054089\">",
"       'Timing of AVF creation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An adequate evaluation of the predialysis patient with chronic kidney disease enhances the opportunity to provide a functioning AVF. This includes a history, physical examination, and arterial and venous evaluation. In adults, we suggest that the artery have a minimum diameter of 2 mm or greater (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patient evaluation prior to access placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even with maximum effort, there are cases in which it is not possible to create one of the three basic types of AVF. Risk factors for AVF failure include inadequate anatomy, obesity, older age, female gender, cardiac disease, and diabetes mellitus. The clinical approach to these patients should be individualized. (See",
"      <a class=\"local\" href=\"#H100368101\">",
"       'Risk factors for AVF failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that a newly created fistula be evaluated between four to six weeks after its creation rather than a later time period (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Fistula maturation should be apparent by this time. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Follow-up to assess maturation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that if a fistula has not matured by 4 to 6 weeks it should be vigorously evaluated for the presence of a correctable lesion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Follow-up to assess maturation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/1\">",
"      Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/2\">",
"      Ascher E, Gade P, Hingorani A, et al. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg 2000; 31:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/3\">",
"      Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/4\">",
"      Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis 2002; 39:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/5\">",
"      A&ntilde;el RL, Yevzlin AS, Ivanovich P. Vascular access and patient outcomes in hemodialysis: questions answered in recent literature. Artif Organs 2003; 27:237.",
"     </a>",
"    </li>",
"    <li>",
"     NKF-K/DOQI Clinical Practice Guidelines For Vascular Access: Update 2006. Guideline 8: Clinical outcome goals, 8.1 goals for access placement, 8.1.2 prevalent functional AVF placement rate.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/7\">",
"      Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/8\">",
"      Miller CD, Robbin ML, Allon M. Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 2003; 63:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/9\">",
"      Hirth RA, Turenne MN, Woods JD, et al. Predictors of type of vascular access in hemodialysis patients. JAMA 1996; 276:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/10\">",
"      Ifudu O, Macey LJ, Homel P, et al. Determinants of type of initial hemodialysis vascular access. Am J Nephrol 1997; 17:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/11\">",
"      Allon M, Ornt DB, Schwab SJ, et al. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Hemodialysis (HEMO) Study Group. Kidney Int 2000; 58:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/12\">",
"      Astor BC, Coresh J, Powe NR, et al. Relation between gender and vascular access complications in hemodialysis patients. Am J Kidney Dis 2000; 36:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/13\">",
"      Peterson WJ, Barker J, Allon M. Disparities in fistula maturation persist despite preoperative vascular mapping. Clin J Am Soc Nephrol 2008; 3:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/14\">",
"      Lok CE, Allon M, Moist L, et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol 2006; 17:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/15\">",
"      Patel ST, Hughes J, Mills JL Sr. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding dialysis outcome quality Initiative guidelines for hemodialysis access. J Vasc Surg 2003; 38:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/16\">",
"      Dhingra RK, Young EW, Hulbert-Shearon TE, et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/17\">",
"      Woods JD, Port FK. The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant 1997; 12:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/18\">",
"      Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/19\">",
"      Perera GB, Mueller MP, Kubaska SM, et al. Superiority of autogenous arteriovenous hemodialysis access: maintenance of function with fewer secondary interventions. Ann Vasc Surg 2004; 18:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/20\">",
"      Fitzgerald JT, Schanzer A, McVicar JP, et al. Upper arm arteriovenous fistula versus forearm looped arteriovenous graft for hemodialysis access: a comparative analysis. Ann Vasc Surg 2005; 19:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/21\">",
"      Keuter XH, De Smet AA, Kessels AG, et al. A randomized multicenter study of the outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis. J Vasc Surg 2008; 47:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/22\">",
"      Pisoni RL, Young EW, Dykstra DM, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/23\">",
"      Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg 2003; 38:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/24\">",
"      Lee T, Barker J, Allon M. Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J Am Soc Nephrol 2007; 18:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/25\">",
"      Oliver MJ, McCann RL, Indridason OS, et al. Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int 2001; 60:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/26\">",
"      Tordoir JH, Rooyens P, Dammers R, et al. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for haemodialysis. Nephrol Dial Transplant 2003; 18:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/27\">",
"      Robbin ML, Chamberlain NE, Lockhart ME, et al. Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology 2002; 225:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/28\">",
"      Valentine RJ, Bouch CW, Scott DJ, et al. Do preoperative finger pressures predict early arterial steal in hemodialysis access patients? A prospective analysis. J Vasc Surg 2002; 36:351.",
"     </a>",
"    </li>",
"    <li>",
"     NKF-K/DOQI Clinical Practice Guidelines For Vascular Access: Update 2006. Guideline 2: Selection and placement of hemodialysis access, 2.1 the order of preference for placement of fistulae, 2.1.1 preferred: fistulae.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/30\">",
"      Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/31\">",
"      Tordoir JH, Dammers R, van der Sande FM. Upper extremity ischemia and hemodialysis vascular access. Eur J Vasc Endovasc Surg 2004; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/32\">",
"      van Hoek F, Scheltinga MR, Kouwenberg I, et al. Steal in hemodialysis patients depends on type of vascular access. Eur J Vasc Endovasc Surg 2006; 32:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/33\">",
"      Jennings WC. Creating arteriovenous fistulas in 132 consecutive patients: exploiting the proximal radial artery arteriovenous fistula: reliable, safe, and simple forearm and upper arm hemodialysis access. Arch Surg 2006; 141:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/34\">",
"      Bonforte G, Rossi E, Auricchio S, et al. The middle-arm fistula as a valuable surgical approach in patients with end-stage renal disease. J Vasc Surg 2010; 52:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/35\">",
"      Bonforte G, Zerbi S, Surian M. The middle-arm fistula: A new native arteriovenous vascular access for hemodialysis patients. Ann Vasc Surg 2004; 18:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/36\">",
"      Jennings WC, Turman MA, Taubman KE. Arteriovenous fistulas for hemodialysis access in children and adolescents using the proximal radial artery inflow site. J Pediatr Surg 2009; 44:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/37\">",
"      Jennings WC, Landis L, Taubman KE, Parker DE. Creating functional autogenous vascular access in older patients. J Vasc Surg 2011; 53:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/38\">",
"      Chemla ES, Morsy MA. Is basilic vein transposition a real alternative to an arteriovenous bypass graft? A prospective study. Semin Dial 2008; 21:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/39\">",
"      Coburn MC, Carney WI Jr. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc Surg 1994; 20:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/40\">",
"      Schild AF, Perez E, Gillaspie E, et al. Arteriovenous fistulae vs. arteriovenous grafts: a retrospective review of 1,700 consecutive vascular access cases. J Vasc Access 2008; 9:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/41\">",
"      Snyder DC, Clericuzio CP, Stringer A, May W. Comparison of outcomes of arteriovenous grafts and fistulas at a single Veterans' Affairs medical center. Am J Surg 2008; 196:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/42\">",
"      Dalman RL, Harris EJ Jr, Victor BJ, Coogan SM. Transition to all-autogenous hemodialysis access: the role of preoperative vein mapping. Ann Vasc Surg 2002; 16:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/43\">",
"      Bourquelot P, Tawakol JB, Gaudric J, et al. Lipectomy as a new approach to secondary procedure superficialization of direct autogenous forearm radial-cephalic arteriovenous accesses for hemodialysis. J Vasc Surg 2009; 50:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/44\">",
"      Krochmal DJ, Rebecca AM, Kalkbrenner KA, et al. Superficialization of deep arteriovenous access procedures in obese patients using suction-assisted lipectomy: A novel approach. Can J Plast Surg 2010; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/45\">",
"      Pisoni RL, Young EW, Mapes DL, et al. Vascular access use and outcomes in the U.S., Europe, and Japan: results from the Dialysis Outcomes and Practice Patterns Study. Nephrol News Issues 2003; 17:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/46\">",
"      Lee T, Barker J, Allon M. Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis 2005; 46:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/47\">",
"      Rayner HC, Besarab A, Brown WW, et al. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/48\">",
"      Friedman AL, Walworth C, Meehan C, et al. First hemodialysis access selection varies with patient acuity. Adv Ren Replace Ther 2000; 7:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/49\">",
"      Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis 2001; 38:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/50\">",
"      Lee T, Barker J, Allon M. Associations with predialysis vascular access management. Am J Kidney Dis 2004; 43:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/51\">",
"      O'Hare AM, Allon M, Kaufman JS. Whether and when to refer patients for predialysis AV fistula creation: complex decision making in the face of uncertainty. Semin Dial 2010; 23:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/52\">",
"      Oliver MJ, Rothwell DM, Fung K, et al. Late creation of vascular access for hemodialysis and increased risk of sepsis. J Am Soc Nephrol 2004; 15:1936.",
"     </a>",
"    </li>",
"    <li>",
"     NKF-K/DOQI Clinical Practice Guidelines For Vascular Access: Update 2006. Guideline 1: Patient preparation for permanent hemodialysis access, 1.3 Patients should have a functional permanent access, 1.3.1 A fistula should be placed at least 6 months before the anticipated start of HD treatments.",
"    </li>",
"    <li>",
"     NKF-K/DOQI Clinical Practice Guidelines For Vascular Access: Update 2006. Guideline 1: Patient preparation for permanent hemodialysis access, 1.4 History and physical examination.",
"    </li>",
"    <li>",
"     Beathard, GA. Complications of vascular access. In: Complications of Dialysis - Recognition and Management. Edited by Lameire, N and Mehta, R. Marcel Dekker, Inc, New York 2000. p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/56\">",
"      Papasavas PK, Reifsnyder T, Birdas TJ, et al. Prediction of arteriovenous access steal syndrome utilizing digital pressure measurements. Vasc Endovascular Surg 2003; 37:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/57\">",
"      Morsy AH, Kulbaski M, Chen C, et al. Incidence and characteristics of patients with hand ischemia after a hemodialysis access procedure. J Surg Res 1998; 74:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/58\">",
"      Silva MB Jr, Hobson RW 2nd, Pappas PJ, et al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg 1998; 27:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/59\">",
"      Agrifoglio M, Dainese L, Pasotti S, et al. Preoperative assessment of the radial artery for coronary artery bypass grafting: is the clinical Allen test adequate? Ann Thorac Surg 2005; 79:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/60\">",
"      Hirai M, Kawai S. False positive and negative results in Allen test. J Cardiovasc Surg (Torino) 1980; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/61\">",
"      Kamienski RW, Barnes RW. Critique of the Allen test for continuity of the palmar arch assessed by doppler ultrasound. Surg Gynecol Obstet 1976; 142:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/62\">",
"      Ruland O, Borkenhagen N, Prien T. [The Doppler palm test]. Ultraschall Med 1988; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/63\">",
"      Paul, BZ, Feeney, CM. Combining the modified Allen's Test and pulse oximetry for evaluating ulnar collateral circulation to the hand for radial artery catheterization of the ED patient. The California Journal of Emergency Medicine 2003; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/64\">",
"      Ferring M, Claridge M, Smith SA, Wilmink T. Routine preoperative vascular ultrasound improves patency and use of arteriovenous fistulas for hemodialysis: a randomized trial. Clin J Am Soc Nephrol 2010; 5:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/65\">",
"      Wong V, Ward R, Taylor J, et al. Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Vasc Endovasc Surg 1996; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/66\">",
"      Malovrh M. Native arteriovenous fistula: preoperative evaluation. Am J Kidney Dis 2002; 39:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/67\">",
"      Ferring M, Henderson J, Wilmink A, Smith S. Vascular ultrasound for the pre-operative evaluation prior to arteriovenous fistula formation for haemodialysis: review of the evidence. Nephrol Dial Transplant 2008; 23:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/68\">",
"      Jennings WC, Kindred MG, Broughan TA. Creating radiocephalic arteriovenous fistulas: technical and functional success. J Am Coll Surg 2009; 208:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/69\">",
"      Bonforte G, Zerbi S, Pasi A, et al. Distal arteriovenous fistulas in elderly hemodialysis patients. J Vasc Access 2000; 1:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/70\">",
"      Fadrowski JJ, Hwang W, Frankenfield DL, et al. Clinical course associated with vascular access type in a national cohort of adolescents who receive hemodialysis: findings from the Clinical Performance Measures and US Renal Data System projects. Clin J Am Soc Nephrol 2006; 1:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/71\">",
"      Leonard MB, Donaldson LA, Ho M, Geary DF. A prospective cohort study of incident maintenance dialysis in children: an NAPRTC study. Kidney Int 2003; 63:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/72\">",
"      Bourquelot P, Raynaud F, Pirozzi N. Microsurgery in children for creation of arteriovenous fistulas in renal and non-renal diseases. Ther Apher Dial 2003; 7:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/73\">",
"      He C, Charoenkul V, Kahn T, et al. Impact of the surgeon on the prevalence of arteriovenous fistulas. ASAIO J 2002; 48:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/74\">",
"      Basile C, Lomonte C. The operating surgeon is the major determinant for a successful arteriovenous fistula maturation. Kidney Int 2007; 72:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/75\">",
"      Fassiadis N, Morsy M, Siva M, et al. Does the surgeon's experience impact on radiocephalic fistula patency rates? Semin Dial 2007; 20:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/76\">",
"      Raynaud A, Novelli L, Bourquelot P, et al. Low-flow maturation failure of distal accesses: Treatment by angioplasty of forearm arteries. J Vasc Surg 2009; 49:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/77\">",
"      Asif A, Leon C, Merrill D, et al. Arterial steal syndrome: a modest proposal for an old paradigm. Am J Kidney Dis 2006; 48:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/78\">",
"      Robbin ML, Gallichio MH, Deierhoi MH, et al. US vascular mapping before hemodialysis access placement. Radiology 2000; 217:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/79\">",
"      Elsharawy MA, Moghazy KM. Impact of pre-operative venography on the planning and outcome of vascular access for hemodialysis patients. J Vasc Access 2006; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/80\">",
"      Nursal TZ, Oguzkurt L, Tercan F, et al. Is routine preoperative ultrasonographic mapping for arteriovenous fistula creation necessary in patients with favorable physical examination findings? Results of a randomized controlled trial. World J Surg 2006; 30:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/81\">",
"      Wells AC, Fernando B, Butler A, et al. Selective use of ultrasonographic vascular mapping in the assessment of patients before haemodialysis access surgery. Br J Surg 2005; 92:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/82\">",
"      Allon M, Lockhart ME, Lilly RZ, et al. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/83\">",
"      Mihmanli I, Besirli K, Kurugoglu S, et al. Cephalic vein and hemodialysis fistula: surgeon's observation versus color Doppler ultrasonographic findings. J Ultrasound Med 2001; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/84\">",
"      van der Linden J, Lameris TW, van den Meiracker AH, et al. Forearm venous distensibility predicts successful arteriovenous fistula. Am J Kidney Dis 2006; 47:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/85\">",
"      Kim JT, Chang WH, Oh TY, Jeong YK. Venous distensibility as a key factor in the success of arteriovenous fistulas at the wrist. Ann Vasc Surg 2011; 25:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/86\">",
"      Caridi JG, Hawkins IF Jr, Wiechmann BN, et al. Sonographic guidance when using the right internal jugular vein for central vein access. AJR Am J Roentgenol 1998; 171:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/87\">",
"      Asif A, Cherla G, Merrill D, et al. Venous mapping using venography and the risk of radiocontrast-induced nephropathy. Semin Dial 2005; 18:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/88\">",
"      Kian K, Wyatt C, Schon D, et al. Safety of low-dose radiocontrast for interventional AV fistula salvage in stage 4 chronic kidney disease patients. Kidney Int 2006; 69:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/89\">",
"      Lauvao LS, Ihnat DM, Goshima KR, et al. Vein diameter is the major predictor of fistula maturation. J Vasc Surg 2009; 49:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/90\">",
"      Salman L, Alex M, Unger SW, et al. Secondary autogenous arteriovenous fistulas in the \"fistula first\" era: results of a longterm prospective study. J Am Coll Surg 2009; 209:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/91\">",
"      Beathard GA. Interventionalist's role in identifying candidates for secondary fistulas. Semin Dial 2004; 17:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/92\">",
"      Asif A, Leon C, Merrill D, et al. Optimal timing for secondary arteriovenous fistula creation: devastating effects of delaying conversion. Semin Dial 2006; 19:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/93\">",
"      Rus RR, Ponikvar R, Kenda RB, Buturovi��-Ponikvar J. Effect of local physical training on the forearm arteries and veins in patients with end-stage renal disease. Blood Purif 2003; 21:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/94\">",
"      Rus RR, Ponikvar R, Kenda RB, Buturovic-Ponikvar J. Effect of intermittent compression of upper arm veins on forearm vessels in patients with end-stage renal disease. Hemodial Int 2005; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/95\">",
"      O'Hare AM, Dudley RA, Hynes DM, et al. Impact of surgeon and surgical center characteristics on choice of permanent vascular access. Kidney Int 2003; 64:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/96\">",
"      Choi KL, Salman L, Krishnamurthy G, et al. Impact of surgeon selection on access placement and survival following preoperative mapping in the \"Fistula First\" era. Semin Dial 2008; 21:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/97\">",
"      Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/98\">",
"      Stolic R. Obesity in renal failure--health or disease? Med Hypotheses 2010; 75:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/99\">",
"      Singh P, Robbin ML, Lockhart ME, Allon M. Clinically immature arteriovenous hemodialysis fistulas: effect of US on salvage. Radiology 2008; 246:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/100\">",
"      Roberts C. Saving a brachiocephalic fistula using lipectomy. Nephrol Nurs J 2005; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/101\">",
"      Barnard KJ, Taubman KE, Jennings WC. Accessible autogenous vascular access for hemodialysis in obese individuals using lipectomy. Am J Surg 2010; 200:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/102\">",
"      Chan MR, Young HN, Becker YT, Yevzlin AS. Obesity as a predictor of vascular access outcomes: analysis of the USRDS DMMS Wave II study. Semin Dial 2008; 21:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/103\">",
"      Kats M, Hawxby AM, Barker J, Allon M. Impact of obesity on arteriovenous fistula outcomes in dialysis patients. Kidney Int 2007; 71:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/104\">",
"      Plumb TJ, Adelson AB, Groggel GC, et al. Obesity and hemodialysis vascular access failure. Am J Kidney Dis 2007; 50:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/105\">",
"      Lazarides MK, Georgiadis GS, Antoniou GA, Staramos DN. A meta-analysis of dialysis access outcome in elderly patients. J Vasc Surg 2007; 45:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/106\">",
"      Weale AR, Bevis P, Neary WD, et al. Radiocephalic and brachiocephalic arteriovenous fistula outcomes in the elderly. J Vasc Surg 2008; 47:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/107\">",
"      Richardson AI 2nd, Leake A, Schmieder GC, et al. Should fistulas really be first in the elderly patient? J Vasc Access 2009; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/108\">",
"      Puskar D, Pasini J, Savi�� I, et al. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J 2002; 43:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/109\">",
"      Obialo CI, Tagoe AT, Martin PC, Asche-Crowe PE. Adequacy and survival of autogenous arteriovenous fistula in African American hemodialysis patients. ASAIO J 2003; 49:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/110\">",
"      Huber TS, Ozaki CK, Flynn TC, et al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J Vasc Surg 2002; 36:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/111\">",
"      Rayner HC, Pisoni RL, Gillespie BW, et al. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003; 63:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/112\">",
"      Marcus RJ, Marcus DA, Sureshkumar KK, et al. Gender differences in vascular access in hemodialysis patients in the United States: developing strategies for improving access outcome. Gend Med 2007; 4:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/113\">",
"      de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/114\">",
"      Beigi AA, Sadeghi AM, Khosravi AR, et al. Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. J Vasc Access 2009; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/115\">",
"      Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/116\">",
"      Yigla M, Abassi Z, Reisner SA, Nakhoul F. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/117\">",
"      Korsheed S, Eldehni MT, John SG, et al. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 2011; 26:3296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/118\">",
"      Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/119\">",
"      Lazarides MK, Georgiadis GS, Tzilalis VD. Diabetes should not preclude efforts for creation of a primary radiocephalic fistula. Nephrol Dial Transplant 2002; 17:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/120\">",
"      Bonucchi, D, Cappelli, G, Albertazzi, A. Which is the preferred vascular access in diabetic patients? A view from Europe. Nephrol Dial Transplant. 2002; 17:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/121\">",
"      Konner, K. Primary vascular access in diabetic patients: an audit. Nephrol Dial Transplant 2000; 15:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/122\">",
"      Murphy GJ, Nicholson ML. Autogeneous elbow fistulas: the effect of diabetes mellitus on maturation, patency, and complication rates. Eur J Vasc Endovasc Surg 2002; 23:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/123\">",
"      Field M, MacNamara K, Bailey G, et al. Primary patency rates of AV fistulas and the effect of patient variables. J Vasc Access 2008; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/124\">",
"      Lin SL, Huang CH, Chen HS, et al. Effects of age and diabetes on blood flow rate and primary outcome of newly created hemodialysis arteriovenous fistulas. Am J Nephrol 1998; 18:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/125\">",
"      Sedlacek M, Teodorescu V, Falk A, et al. Hemodialysis access placement with preoperative noninvasive vascular mapping: comparison between patients with and without diabetes. Am J Kidney Dis 2001; 38:560.",
"     </a>",
"    </li>",
"    <li>",
"     Fistula First. file://fistulafirst.org/LinkClick.aspx?fileticket=9R1VX2YjIWA%3d&amp;tabid=117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/127\">",
"      Germain MJ, Cohen LM. Maintaining quality of life at the end of life in the end-stage renal disease population. Adv Chronic Kidney Dis 2008; 15:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/128\">",
"      Beathard, GA. Physical examination of AV grafts. Semin Dial 1992; 5:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/129\">",
"      Trerotola SO, Ponce P, Stavropoulos SW, et al. Physical examination versus normalized pressure ratio for predicting outcomes of hemodialysis access interventions. J Vasc Interv Radiol 2003; 14:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/130\">",
"      Trerotola SO, Scheel PJ Jr, Powe NR, et al. Screening for dialysis access graft malfunction: comparison of physical examination with US. J Vasc Interv Radiol 1996; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/131\">",
"      Asif A, Leon C, Orozco-Vargas LC, et al. Accuracy of physical examination in the detection of arteriovenous fistula stenosis. Clin J Am Soc Nephrol 2007; 2:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/132\">",
"      Schuman E, Ronfeld A, Barclay C, Heinl P. Comparison of clinical assessment with ultrasound flow for hemodialysis access surveillance. Arch Surg 2007; 142:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/133\">",
"      Beathard GA. An algorithm for the physical examination of early fistula failure. Semin Dial 2005; 18:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/134\">",
"      Yerdel MA, Kesenci M, Yazicioglu KM, et al. Effect of haemodynamic variables on surgically created arteriovenous fistula flow. Nephrol Dial Transplant 1997; 12:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/135\">",
"      Malovrh M. Non-invasive evaluation of vessels by duplex sonography prior to construction of arteriovenous fistulas for haemodialysis. Nephrol Dial Transplant 1998; 13:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/21/37210/abstract/136\">",
"      Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299:2164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1917 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37210=[""].join("\n");
var outline_f36_21_37210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CHARACTERISTICS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TYPES OF NATIVE AVF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368959032\">",
"      Types by method of creation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Simple direct fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Vein transposition fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vein translocation fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Types by anatomic location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radial-cephalic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Brachial-cephalic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Brachial-basilic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ORDER OF PREFERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      AVF REQUIREMENTS FOR USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28054066\">",
"      Anatomic accessibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Superficial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Straight segment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28054078\">",
"      Blood flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28054089\">",
"      TIMING OF AVF CREATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PATIENT EVALUATION PRIOR TO ACCESS PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arterial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Assessment of pulses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Allen test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Arterial imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100368021\">",
"      - Arterial requirements for AVF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Venous evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107109543\">",
"      - Vein mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Venography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Choice between ultrasound and venography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107109520\">",
"      - Venous requirements for AVF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Patients with inadequate vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100368101\">",
"      RISK FACTORS FOR AVF FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107109965\">",
"      Inadequate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100368056\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100368063\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28054142\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107110138\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107110166\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107110386\">",
"      Approach in high-risk patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      FOLLOW-UP TO ASSESS MATURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1917\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1917|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/3/18480\" title=\"figure 1A\">",
"      Anterior view superficial veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/43/16053\" title=\"figure 1B\">",
"      Deep veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1917|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/6/41057\" title=\"picture 1\">",
"      Handheld Doppler",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12536?source=related_link\">",
"      Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18010?source=related_link\">",
"      Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41443?source=related_link\">",
"      Physical examination of the hemodialysis arteriovenous fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11944?source=related_link\">",
"      Use of stents for venous stenosis associated with dialysis vascular access",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_21_37211="Bronchial wall puncture";
var content_f36_21_37211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Techniques used for transbronchial wall penetration during TBNA*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Jabbing method",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The needle is thrust through the intercartilaginous space with a quick, firm jab to the catheter, while the scope is fixed at the nose or mouth.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hub against the wall method",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With the needle in the retracted position, the distal end of the catheter (the metal hub) can be placed directly in contact with the target and held firmly while the needle is pushed out of the catheter for its spontaneous penetration through the tracheobronchial wall.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Piggyback method",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Once the needle is advanced and locked in position, the catheter is fixed against the proximal end of the insertion port using the index finger in a single port scope or the little finger in a dual port scope to prevent recoil when resistance is met. The bronchoscope and catheter are then pushed forward as a single unit, until the entire needle penetrates the tracheobronchial wall.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cough method",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        While the jabbing or piggyback technique is applied, the patient is asked to give a hard cough for the spontaneous penetration of the needle.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These techniques may be used alone or in combination for successful penetration of the needle through the tracheobronchial wall.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37211=[""].join("\n");
var outline_f36_21_37211=null;
var title_f36_21_37212="Five Ps of sexual history";
var content_f36_21_37212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The five P's: Partners, prevention of pregnancy, protection from STDs, practices, and past history of STDs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Partners",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you have sex with men, women, or both?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the past 2 months, how many partners have you had sex with?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the past 12 months, how many partners have you had sex with?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is it possible that any of your sex partners in the past 12 months had sex with someone else while they were still in a sexual relationship with you?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prevention of pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What are you doing to prevent pregnancy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Protection from STDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What do you do to protect yourself from STDs and HIV?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Practices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To understand your risks for STDs, I need to understand the kind of sex you have had recently.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you had vaginal sex, meaning 'penis-in-vagina' sex?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        If yes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do you use condoms: never, sometimes, or always?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you had anal sex, meaning 'penis-in rectum/anus' sex?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        If yes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Do you use condoms: never, sometimes, or always?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you had oral sex, meaning 'mouth-on-penis/vagina'?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For condom answers:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If never:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Why don't you use condoms?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If sometimes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        In what situations (or with whom) do you not use condoms?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Past history of STDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you ever had an STD?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have any of your partners had an STD?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional questions to identify HIV and viral hepatitis risk:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you or any of your partners ever injected drugs?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you or any of your partners exchanged money or drugs for sex?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is there anything else about your sexual practices that I need to know about?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     STD: sexually transmitted disease; HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Workowski KA, Berman SM. Sexually transmitted diseases guidelines, 2010. MMWR Recomm Rep 2010; 59(No.RR-12):3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37212=[""].join("\n");
var outline_f36_21_37212=null;
var title_f36_21_37213="Lifetime psych dx IEI";
var content_f36_21_37213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Number of lifetime (current and past) psychiatric diagnoses in 295 patients with symptoms of idiopathic environmental intolerance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Psychiatric disorder",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Number of diagnoses (N = 435)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        n",
"       </td>",
"       <td class=\"subtitle2\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Somatoform disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        113",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Somatoform disorder not otherwise specified",
"       </td>",
"       <td class=\"indent1\">",
"        61",
"       </td>",
"       <td class=\"indent1\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pain disorder",
"       </td>",
"       <td class=\"indent1\">",
"        27",
"       </td>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Somatization disorder",
"       </td>",
"       <td class=\"indent1\">",
"        18",
"       </td>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypochondriasis",
"       </td>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Mood disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        95",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Major depression",
"       </td>",
"       <td class=\"indent1\">",
"        62",
"       </td>",
"       <td class=\"indent1\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysthymia",
"       </td>",
"       <td class=\"indent1\">",
"        27",
"       </td>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bipolar disorder",
"       </td>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anxiety disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        75",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Agoraphobia",
"       </td>",
"       <td class=\"indent1\">",
"        24",
"       </td>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Panic disorder",
"       </td>",
"       <td class=\"indent1\">",
"        17",
"       </td>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive-compulsive disorder",
"       </td>",
"       <td class=\"indent1\">",
"        7",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generalized anxiety disorder",
"       </td>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Social phobia",
"       </td>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anxiety disorder not otherwise specified",
"       </td>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specific phobia",
"       </td>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Posttraumatic stress disorder",
"       </td>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Substance use disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        63",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol abuse or dependence",
"       </td>",
"       <td class=\"indent1\">",
"        37",
"       </td>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sedative abuse or dependence",
"       </td>",
"       <td class=\"indent1\">",
"        12",
"       </td>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cannabis abuse or dependence",
"       </td>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amphetamine abuse or dependence",
"       </td>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Personality disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        53",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive-compulsive",
"       </td>",
"       <td class=\"indent1\">",
"        15",
"       </td>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoidant",
"       </td>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schizoid",
"       </td>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Psychotic disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        16",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Eating disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        3",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other disorders",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        17",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hausteiner, C, Bornschein, S, Bickel, H, et al. Psychiatric morbidity and low self-attentiveness in patients with environmental illness. J Nerv Ment Dis 2003; 191:50.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37213=[""].join("\n");
var outline_f36_21_37213=null;
var title_f36_21_37214="Schatzki ring healed CPC Endosc";
var content_f36_21_37214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schatzki's ring healed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the distended distal esophagus revealing complete healing of the superficial ulceration with a ring of thin membrane occluding 70 percent of the distal esophageal lumen. This is the characteristic endoscopic view of a Schatzki ring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas A. Horst, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37214=[""].join("\n");
var outline_f36_21_37214=null;
var title_f36_21_37215="Plat 2nd messenger production";
var content_f36_21_37215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fate of phosphatidylinositol 4,5-biphosphate (PIP2) in platelets and second messenger production",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the outcome of agonist activation of platelet phospholipase C beta (PLC) via the G alpha-q subunit and activation of phosphoinositol 3-kinase gamma (PI3K) via the G beta-gamma subunit. In both cases, the substrate is membrane-associated phosphatidylinositol 4,5-biphosphate (PIP2), shown in the top center of the figure. The green arrows point to the number 1 and 3 carbons in the inositol ring. Hydrolysis of PIP2 by PLC yields 1,4,5-inositol triphosphate (IP3), which raises the cytosolic Ca++ concentration by releasing sequestered Ca++ from the dense tubular system and diacylglycerol (DAG), which activates protein kinase C. Phosphorylation of the number 3 inositol carbon of PIP2 by PI3K generates the second messenger phosphoinositol 3,4,5-triphosphate (PIP3), important for stable platelet aggregation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_21_37215=[""].join("\n");
var outline_f36_21_37215=null;
